

## DAFTAR PUSTAKA

- Aboutaleb H, Gawesh M (2016). *Bladder histopathological changes due to ureteral double-J stenting in 30 patients: A prospective study*. Eur Urol Suppl.
- Abrams P, Andersson KE, Buccafusco JJ, (2006). *Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder*. Br J Pharmacol. 2006;148(5):565-578. doi:10.1038/sj.bjp.0706780
- Adams J.L., James K., Moore M. (2016). *Cancer Immunotherapy—An Emerging Field That Bridges Oncology and Immunology Research*. December 2016, DOI: 10.1016/B978-0-12-409547-2.12400-X
- Acharya D, Sullivan MJ, Duell BL, Goh KKG, Katupitiya L, Goslin D, et al. (2019). Rapid bladder interleukin-10 synthesis in response to uropathogenic *Escherichia coli* is part of a defense strategy triggered by the major bacterial flagellar filament FliC and contingent on TLR5. American Society for Microbiology 2019;4(6):e00545-19. doi: 10.1128/mSphere.00545-19.
- Aizawa N, Homma Y, Igawa Y (2012) Effects of mirabegron, a novel  $\beta_3$ -adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol 62: 1165-1173. Link: <https://bit.ly/3sIYKmq>
- Akdis M, Burgler S, Cramer R, (2011). *Interleukins, from 1 to 37, and interferon- $\gamma$ : receptors, functions, and roles in diseases* [published correction appears in J Allergy Clin Immunol. 2011 Oct;128(4):739. Quaked, Nadia [corrected to Ouaked, Nadia]]. *J Allergy Clin Immunol*. 2011;127(3):701-21.e270. doi:10.1016/j.jaci.2010.11.050
- Alexander K, Palinrungi A, Palinrungi MA, Kholis K, Syahrir S, Syarif S, (2020). *Effectiveness of Tamsulosin compared with Mirabegron in treatment of Double-J Stent-Related Lower Urinary Tract Symptoms*. Int J Med Rev Case Reports. 2020;4(0):1.
- Alexandre EC, Kiguti LR, Calmasini FB, Silva FH, da Silva KP, Ferreira R, et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3-adrenoceptor activation and alpha1-adrenoceptor blockade. Br J Pharm. 2016;173:415–28
- Andersson K-E, McCloskey KD (2014). *Lamina propria: The functional center of the bladder?* *Neurourol Urodyn* [Internet]. [Updated 2014 Jan;33(1):9–16, cited 2021 Feb 10]. Available from: <http://doi.wiley.com/10.1002/nau.22465>
- Andersson KE (2017). *On the Site and Mechanism of Action of  $\beta_3$ -Adrenoceptor Agonists in the Bladder*. Int Neurourol J. 2017;21(1):6-11. Published 2017 Mar 24. doi:10.5213/inj.1734850.425
- Andersson KE, Choudhury N, Cornu JN, Huang M, Korstanje C, Siddiqui E, (2018). *The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy*. Therapeutic Advances in Urology.
- Anjum I. Calcium sensitization mechanisms in detrusor smooth muscles. J Basic Clin Physiol Pharmacol. 2018;29:227-235.

- Ateyah MA, Abdulridha MK, Alkabee MJ (2021) Effects of Saw Palmetto Therapy on some Inflammatory Biomarkers in a Sample of Iraqi Male with Symptomatic Benign Prostatic Hyperplasia. *Al Mustansiriyah J Pharm Sci* 21:1–9.
- Bantis A, Tsakalidis G, Zissimopoulos A, Giannakopoulos S, Kalaitzis C, Pitiakoudis M, (2014). *Can Tumor Necrosis Factor-  $\alpha$  and Interleukin-6 Be Used as Prognostic Markers of Infection following Ureteroscopic Lithotripsy?* ISRN Urol [Internet]. [Updated 2014;2014:1–5; cited 2021 Feb 10]. Available from: <https://www.hindawi.com/archive/2014/457063/>
- Basu M (2020). *Management of overactive bladder*. *Obstet Gynaecol Reprod Med*. 2020;30(1):1–5.
- Bedard K., Krause K., (2007). *The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.*, *Physiological Reviews*, Published Online: 2007 Jan 01, DOI: 10.1152/physrev.00044.2005
- Beinke S., Ley S.(2011). *Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology*. *Biochem J*, 2004 Sep 1;382(Pt 2):393-409, doi: 10.1042/BJ20040544Shao-Cong Sun (2011): Non-canonical NF- $\kappa$ B signaling pathway. DOI: 10.1038/cr.2010.177.
- Bhattar R, Tomar V, Yadav SS, Dhakad DS (2018). *Comparison of safety and efficacy of silodosin, solifenacin, tadalafil and their combinations in the treatment of double-J stent- related lower urinary system symptoms: A prospective randomized trial*. *Türk Üroloji Dergisi/Turkish J Urol* [Internet]. [Updated 2018 Jun 1;228–38; cited 2021 Feb 10]. Available from: <https://www.turkishjournalofurology.com/en/comparison-of-safety-and-efficacy-of-silodosin-solifenacin-tadalafil-and-their-combinations-in-the-treatment-of-double-j-stent-related-lower-urinary-system-symptoms-a-prospective-randomized-trial-133253>
- Buhmann MT, Abt D, Nolte O, Neu TR, Stempel S, Albrich WC, (2019). *Encrustations on stent ureters from patients without urinary tract infection reveal distinct urotypes and a low bacterial load*. *Microbiome* [Internet]. [Updated 2019 Dec 13;7(1):60; cited 2021 Jan 27]. Available from: <https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-019-0674-x>
- Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. *Pharmacol Rev*. 1994;46:121-136.
- Cao W, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, Dixon TM, Lefkowitz RJ, Collins S. Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation. *J Biol Chem*. 2000 Dec 8;275(49):38131-4. doi: 10.1074/jbc.C000592200. PMID: 11013230.
- Chai TC, Russo A, Yu S, Lu M (2016). *Mucosal signaling in the bladder*. *Auton Neurosci* [Internet]. [Updated 2016 Oct;200:49–56; cited 2021 Feb 10]. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1566070215300230>
- Chandna A, Kumar S, Parmar KM, et al. Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial. *Urologia Journal*. 2022;89(4):589-596. doi:10.1177/03915603211048153
- Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, (2020). *Safety and Efficacy of*

- Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo*[Formula presented]. *Eur Urol* [Internet]. [Updated 2020;77(1):119–28; 2021 Feb 10]. Available from: <https://doi.org/10.1016/j.eururo.2019.09.024>
- Chen Z, Ognenovska S, Sluyter R, Moore KH, Mansfield KJ. Urinary cytokines in women with refractory detrusor overactivity: A longitudinal study of rotating antibiotic versus placebo treatment. *PLoS One*. 2021 Mar 3;16(3):e0247861. doi: 10.1371/journal.pone.0247861. PMID: 33657181; PMCID: PMC7928483.
- Chu WM (2013). *Tumor necrosis factor*. *Cancer Lett*. 2013;328(2):222-225. doi:10.1016/j.canlet.2012.10.014
- Corcos J, Przydacz M, Campeau L, et al. *CUA guideline on adult overactive bladder* [published correction appears in *Can Urol Assoc J*. 2017 May;11(5):E250] [published correction appears in *Can Urol Assoc J*. 2017 Jul;11(7):E323]. *Can Urol Assoc J*. 2017;11(5):E142-E173. [cited 2021 Feb 10]. doi:10.5489/cuaj.4586
- da Silva CPV, Calmasini F, Alexandre EC, Raposo HF, Delbin MA, Monica FZ, Zanesco A (2021) The effects of mirabegron on obesity-induced inflammation and insulin resistance are associated with brown adipose tissue activation but not being in the subcutaneous white adipose tissue. *Clin Exp Pharmacol Physiol* 48:1477–1487
- Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. *J Endourol*. 2008 Apr;22(4):651-6. doi: 10.1089/end.2007.0257. PMID: 18338955.
- Dawood O, El-Zawahry A (2020). *Mirabegron*. [Updated 2020 Jul 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-‘ [cited 2021 Jan 07]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538513/>
- Debnath P, Huirem RS, Dutta P, Palchadhuri S. Epithelial–mesenchymal transition and its transcription factors. *Biosci Rep* 28 January 2022; 42 (1): BSR20211754. doi: <https://doi.org/10.1042/BSR20211754>
- Deliveliotis K, Papatsoris AG, Skolarikos A, Mitsogiannis I, Tzannis K, Dellis AE (2020). *Management of stent-related symptoms with the use of  $\alpha$ -blockers: A meta-analysis*. *Arab J Urol* [Internet]. [Updated 2020 Jan 2;18(1):14–2; cited 2021 Feb 10]. Available from: <https://www.tandfonline.com/doi/full/10.1080/2090598X.2019.1690824>
- Dellis AE, Papatsoris AG, Keeley FX, Bamias A, Deliveliotis C, Skolarikos AA(2017). *Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study*. *J Endourol* [Internet]. [Updated 2017 Jan;31(1):100–9; cited 2021 Feb 10]. Available from: <http://www.liebertpub.com/doi/10.1089/end.2016.0663>
- Delnay KM, Stonehill WH, Goldman H, Jukkola AF, Dmochowski RR (1999). *Bladder histological changes associated with chronic indwelling urinary catheter*. *J Urol* [Internet]. [Updated 1999

- Apr;161(4):1106–8; discussion 1108-9; cited 2021 Jan 27]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10081848>
- Dimitropoulos K, Gravas S. New therapeutic strategies for the treatment of male lower urinary tract symptoms. *Res Rep Urol*. 2016;8:51-59 <https://doi.org/10.2147/RRU.S63446>
- Duell BL, Carey AJ, Dando SJ, Schembri MA, Ulett GC (2013) Human Bladder Uroepithelial Cells Synergize with Monocytes to Promote IL-10 Synthesis and Other Cytokine Responses to Uropathogenic Escherichia coli. *PLoS ONE* 8(10): e78013. doi:10.1371/journal.pone.0078013
- Dyer RB, Chen MY, Zagoria RJ, Regan JD, Hood CG, Kavanagh P V (2002). *Complications of stent ureter placement*. *Radiographics* [Internet]. [Updated 2002 Sep 22(5):1005–22; cited 2021 Jan 27]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12235330>
- Elwood CN, Lange D, Nadeau R, Seney S, Summers K, Chew BH (2010). *Novel in vitro model for studying ureteric stent-induced cell injury*. *BJU Int* [Internet]. [Updated 2010 May;105(9):1318–23, cited 2021 Jan 27]. Available from: <http://doi.wiley.com/10.1111/j.1464-410X.2009.09001.x>
- Farshi Haghro A, Hajebrahimi S, Jabbari A, Sadeghi H, Babaei H (2019). *Efficacy of Tadalafil on Stent ureter Symptoms: A Randomized Controlled Trial*. *Nephrourol Mon* [Internet]. [Updated 2019 Feb 5;In Press(In Press); cited 2021 Feb 10]. Available from: <https://sites.kowsarpub.com/num/articles/85523.html>
- Finkel T(2001). *Signal transduction by reactive oxygen species*, *J Cell Biol* 2001 Jul 11; 194(1): 7-15, DOI: 10.1083/jcb.201102095
- Fry CH, Vahabi B. *The Role of the Mucosa in Normal and Abnormal Bladder Function*. *Basic Clin Pharmacol Toxicol* [Internet]. 2016 Oct;119:57–62. Available from: <http://doi.wiley.com/10.1111/bcpt.12626>
- Furuta A, Yamamoto T, Suzuki Y, Gotoh M, Egawa S, Yoshimura N (2018) Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. *Int Urogynecol J* [Internet]. [Updated 2018 Jul 25;29(7):961–6; cited 2021 Jan 21]. Available from: <http://link.springer.com/10.1007/s00192-017-3547-5>
- Gabay C (2006). *Interleukin-6 and chronic inflammation*. *Arthritis Res Ther*.
- Gandhirajan R. (2013). *Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation*. *J Clin Invest*. 2013 Feb; 123 (2): 887-902, DOI: 10.1172/JCI6564
- Giannarini G, Keeley Jr FX, Valent F, Manassero F, Mogorovich A, Autorino R, (2011). *Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire*. *BJU Int* [Internet]. [Updated 2011 Feb;107(4):648–54; cited 2021 Jan 27]. Available from: <http://doi.wiley.com/10.1111/j.1464-410X.2010.09482.x>
- Goble NM, Clarke T, Hammonds JC. Histological changes in the urinary bladder secondary to urethral catheterisation. *Br J Urol*. 1989 Apr;63(4):354-7. doi: 10.1111/j.1464-410x.1989.tb05216.x. PMID: 2713616.

- Gonzalez EJ, Arms L, Vizzard MA (2014). *The Role(s) of Cytokines/Chemokines in Urinary Bladder Inflammation and Dysfunction*. Biomed Res Int [Internet]. [Updated 2014;2014:1–17; cited 2021 Jan 27]. Available from: <http://www.hindawi.com/journals/bmri/2014/120525/>
- Goulooze SC, Cohen AF, Rissmann R (2015). *Mirabegron*. Br J Clin Pharmacol. 2015;80(4):762–4.
- Griffin JJ, Cheng SK (Kevin), Hayashi T, Carson D, Saraswathy M, Nair DP, (2017). *Cell-penetrating peptide CGKRRK mediates efficient and widespread targeting of bladder mucosa following focal injury*. Nanomedicine Nanotechnology, Biol Med [Internet]. [Updated 2017 Aug;13(6):1925–32; cited 2021 Feb 10]. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1549963417300655>
- Grover S, Srivastava A, Lee R, Tewari AK, Te AE (2011). *Role of inflammation in bladder function and interstitial cystitis*. Ther Adv Urol [Internet]. [Updated 2011 Feb;3(1):19–33; cited 2021 Feb 10]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21789096>
- Gubbiotti, M., Giannantoni, A., Cantaluppi, S. *et al.* The impact of Mirabegron on sexual function in women with idiopathic overactive bladder. *BMC Urol* **19**, 7 (2019). <https://doi.org/10.1186/s12894-019-0438-8>
- Günthner R., Anders H. (2013). *Interferon-Regulatory Factors Determine Macrophage Phenotype Polarization*. Mediators Inflamm. 2013;2013:731023, DOI: 10.1155/2013/731023
- Gur S, Peak T, Yafi FA, Kadowitz PJ, Sikka SC, Hellstrom WJ. Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction? *BJU Int*. 2016;118:464–74
- Grover S, Srivastava A, Lee R, Tewari AK, Te AE. Role of inflammation in bladder function and interstitial cystitis. *Ther Adv Urol*. 2011 Feb;3(1):19–33. doi: 10.1177/1756287211398255. PMID: 21789096; PMCID: PMC3126088.
- Hadi T.(2017). Beta3 adrenergic receptor stimulation in human macrophages inhibits NADPHoxidase activity and induces catalase expression via PPAR $\gamma$  activation. *Biochim Biophys Acta Mol Cell Res*, 2017 Oct;1864(10):1769–1784. DOI: 10.1016/j.bbamcr.2017.07.003
- Hang L, Svanborg C, Andersson G (1994). *Determination of Interleukin 6 in Human Urine and Epithelial Cell Supernatants*. Int Arch Allergy Immunol [Internet]. [Updated 1994;105(4):397–403; cited 2021 Feb 10]. Available from: <https://www.karger.com/Article/FullText/236790>
- Hang L, Wullt B, Shen Z, Karpman D, Svanborg C (1998). *Cytokine repertoire of epithelial cells lining the human urinary tract*. J Urol [Internet]. [Updated 1998 Jun;159(6):2185–92; cited 2021 Feb 10]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9598567>
- Hayden M., Ghosh S. (2011). *NF- $\kappa$ B in immunobiology*. published 2011 January 18, Cell Research 21, 223–244. doi: 10.1038/cr.2011.13.
- Hayden M., Ghosh S.,(2008). *Shared principles in NF-kappaB signaling*, 2008 February 08, Cell volume 132, issue 3, P344–362 doi: 10.1016/j.cell.2008.01.020.
- Hoesel Bastian, Shmid Johannes (2013). *The complexity of NF- $\kappa$ B signaling in inflammation and cancer*.

- Molecular Cancer 12, article Number: 86 (2013), DOI: 10.1186/1476-4598-12-86.
- Hu H., Sun S (2016). *Ubiquitin signaling in immune responses*. Published: 2016 March 25, Cell Research 26,457-83(2016), <https://doi.org/10.1038/cr.2016.40>
- Huang R, Liu Y, Ciotkowska A, Tamalunas A, Waidelich R, Strittmatter F, Stief CG, Hennenberg M. Concentration-dependent alpha1-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate. *Front Pharmacol*. 2021 Jun 24;12:666047. doi: 10.3389/fphar.2021.666047. PMID: 34248624; PMCID: PMC8264149.
- Igawa Y, Aizawa N, Homma Y (2010). *Beta3-adrenoceptor agonists: Possible role in the treatment of overactive bladder*. *Korean J Urol*. 2010;51(12):811–8.
- Inn FX, Ahmed N, Hou LG, Abidin ZAZ, Yi LL, Zainuddin ZM (2019). *Intravesical stent position as a predictor of quality of life in patients with indwelling stent ureter*. *Int Urol Nephrol* [Internet]. [Updated 2019 Nov 22;51(11):1949–53; cited 2021 Jan 27]. Available from: <http://link.springer.com/10.1007/s11255-019-02262-7>
- Islam H, Chamberlain TC, Mui AL and Little JP (2021) Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action? *Front. Immunol*. 12:677008. doi: 10.3389/fimmu.2021.677008
- Israël A.(2010), *The IKK complex, a central regulator of NF-kappaB activation*. *Cold Spring harb Perspect Biol*. 2010 Mar;2(3):a000158, doi: 10.1101/cshperspect.a000158.
- Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. *Crit Rev Immunol*. 2012;32(1):23-63. doi:10.1615/critrevimmunol.v32.i1.30
- Janssen, C., Buttyan, R., Seow, C.Y., Jäger, W., Solomon, D., Fazli, (2017). *A Role for the Hedgehog Effector Gli1 in Mediating Stent-induced Ureteral Smooth Muscle Dysfunction and Aperistalsis*. *Urology* 104, 242.e1-242.e8. <https://doi.org/10.1016/j.urology.2017.01.029>
- Jantusch BA, O'Donnell R, Wiedermann BL (2000). *Urinary interleukin-6 and interleukin-8 in children with urinary tract infection*. *Pediatr Nephrol* [Internet]. [Updated 2000 Dec;15(3–4):236–40; cited 2021 Feb 10]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11149117>
- Jhang J-F, Kuo H-C (2016). *Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease*. *Int Neurourol J* [Internet]. 2016 Nov 30;20(Suppl 2):S95-104. Available from: <http://ejn.org/journal/view.php?doi=10.5213/inj.1632712.356>
- Jiang YH, Jhang JF, Hsu YH, Ho HC, Wu YH, Kuo HC. Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. *Sci Rep*. 2021 Jan 13;11(1):914. doi: 10.1038/s41598-020-80131-5. PMID: 33441752; PMCID: PMC7806856.
- Jo JK, Kim JH, Kim KS, Chung JH, Kim YT, Choi HY, (2018). *Effect of highly concentrated hyaluronic acid/chondroitin sulphate instillation on ureteric stent-induced discomfort after ureteroscopic lithotripsy: a multicentre randomised controlled pilot study*. *BJU Int* [Internet]. [Updated 2018 Nov;122(5):858–65; cited 2021 Jan 27]. Available from: <http://doi.wiley.com/10.1111/bju.14392>

- Justiz Vaillant AA, Qurie A (2020). *Interleukin*. In: StatPearls [Internet]. Treasure Island (FL): [Updated 2020 Aug 30; cited 2021 Feb 10]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499840/>
- Kallner HK, Christensson AA, Elmér C, Flam B, Altman D (2016). *Safety and efficacy of mirabegron in daily clinical practice: A prospective observational study*. Eur J Obstet Gynecol Reprod Biol. 2016;203:167–72.
- Kang Y, Su G, Sun J, Zhang Y. Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A. Oncol Lett. 2018;15(6):9647-9654. doi:10.3892/ol.2018.8586
- Karakus, S., Musicki, B., & Burnett, A. L. (2021). Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study. International Journal of Impotence Research. doi:10.1038/s41443-021-00455-2
- Karin M., Delhase M. (2000). *The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling*. Semin Immunol. 2000 feb;12(1):85-98, doi: 10.1006/smim.2000.0210.
- Kato D, Tabuchi H, Uno S. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study. LUTS Low Urine Tract Symptoms. 2019;11(2):O152–61.
- Ke Q-S, Kuo H-C (2015). *Pathophysiology of interstitial cystitis/bladder pain syndrome*. Tzu Chi Med J [Internet]. [Updated 2015 Dec;27(4):139–44.; cited 2021 Feb 10]. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1016319015000889>
- Keay, S.K., Birdier, L.A., Chai, T.C., (2014). *Evidence for bladder urothelial pathophysiology in functional bladder disorders*. Biomed Res. Int. 2014. <https://doi.org/10.1155/2014/865463>
- Kehinde EO, Rotimi VO, Al-Awadi KA, Abdul-Halim H, Boland F, Al-Hunayan A, (2002). *Factors predisposing to urinary tract infection after J stent ureter insertion*. J Urol [Internet]. [Updated 2002 Mar;167(3):1334–7; cited 2021 Jan 27]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11832726>
- Klingler CH. Glycosaminoglycans: how much do we know about their role in the bladder? Urologia. 2016 Jun 25;83 Suppl 1:11-4. doi: 10.5301/uro.5000184. Epub 2016 Jun 23. PMID: 27405344.
- Kovács ZZA, Szűcs G, Freiwan M, et al. (2021) Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy. Sci Rep 11:1–18
- Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, (2012). *Pharmacokinetic Properties of Mirabegron, a  $\beta$ 3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women*. Clin Ther [Internet]. [Updated 2012;34(10):2144–60; cited 2021 Feb 10]. Available from: <http://dx.doi.org/10.1016/j.clinthera.2012.09.010>
- Krauwinkel WJJ, Kerbusch VMM, Meijer J, Tretter R, Strabach G, Van Gelderen EM (2013). Evaluation

of the pharmacokinetic interaction between the  $\beta$ 3-adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects. *Clin Pharmacol Drug Dev.* 2013;2(3):255–63.

- Kuo H-C, Liu H-T, Shie J-H (2013). *Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome.* *Tzu Chi Med J* [Internet]. [Update 2013 Mar;25(1):13–8; cited 2021 Jan 27]. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S101631901200119X>
- Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-analysis showing the beneficial effect of  $\alpha$ -blockers on ureteric stent discomfort. *BJU Int* 2011;108(11):1894–1902
- Lampropoulou IT, Stangou M, Papagianni A, Didangelos T, Iliadis F, Efstratiadis G (2014). *TNF-  $\alpha$  and microalbuminuria in patients with type 2 diabetes mellitus.* *J Diabetes Res.*
- Lange D., Bidnur S., Hoag N., Chew B.H (2015). *Stent ureter-associated complications—where we are and where we are going.* *Nat Rev Urol* [Internet]. [Updated 2015 Jan 23;12(1):17–25; cited 2021 Jan 27]. Available from: <http://www.nature.com/articles/nrurol.2014.340>
- Lawrence T. (2009). *The nuclear factor NF-kappaB pathway in inflammation.* *Cold Spring Harb Perspect Biol.* 2009 Dec;1(6):a001651, doi: 10.1101/cshperspect.a001651.
- Lee JN, Kim BS (2015). *Comparison of efficacy and bladder irritation symptoms among three different stent ureters: A double-blind, prospective, randomized controlled trial.* *Scand J Urol* [Internet]. [Updated 2015 May 4;49(3):237–41; cited 2021 Jan 27]. Available from: <http://www.tandfonline.com/doi/full/10.3109/21681805.2014.981205>
- Lee S-W, Hsiao P-J, Chang C-H, Chou E-L (2018). *Lower urinary tract symptoms associated with double-J stent.* *Urol Sci* [Internet]. [Updated 2018; cited 2021 Jan 27]. Available from: <http://www.e-urol-sci.com/preprintarticle.asp?id=240952>
- Li Z, Cui Y, Chai Y, Zhang Y. The efficacy and safety of mirabegron in treating ureteral stent-related symptoms: A systematic review and meta-analysis. *Low Urin Tract Symptoms.* 2022 Jan;14(1):27-34. doi: 10.1111/luts.12405. Epub 2021 Aug 6. PMID: 34363321.
- Lim KT, Kim YT, Lee TY, Park SY (2011). *Effects of Tamsulosin, Solifenacin, and Combination Therapy for the Treatment of Stent ureter Related Discomforts.* *Korean J Urol* [Internet]. [Updated 2011;52(7):485; cited 2021 Feb 10]. Available from: <https://icurology.org/DOIx.php?id=10.4111/kju.2011.52.7.485>
- Lin C., Lee I., Yang Y., Lee C., Kou Y, Yang C. (2010). *Induction of COX-2/PGE2/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: Role of TLR4-dependent NADPH oxidase activation.* *Free Radic Biol Med*, DOI: 10.1016/j.freeradbiomed.2009.10.047
- Lin S, Chengmin S, Shibo Z, Lan Z, Wenping H. (2021) Tamsulosin attenuates high glucose-induced injury in glomerular endothelial cells, *Bioengineered*, 12:1, 5184-5194, DOI: 10.1080/21655979.2021.1955527
- Liu Q, Luo D, Yang T, Liao B, Li H, Wang K-J (2017). *Protective Effects of Antimuscarinics on the*



- Bladder Remodeling After Bladder Outlet Obstruction*. Cell Physiol Biochem [Internet]. 2017;44(3):907–19. Available from: <https://www.karger.com/Article/FullText/485358>
- Liu S, Yu Y, Gao Y, Yang X, Pang Z. Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study. *Urolithiasis*. 2016 Apr;44(2):185-90. doi: 10.1007/s00240-015-0810-4. Epub 2015 Aug 5. PMID: 26242466.
- Liu HT, Jiang YH, Kuo HC. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. *PLoS One*. 2013 Oct 1;8(10):e76706. doi: 10.1371/journal.pone.0076706. PMID: 24098552; PMCID: PMC3788120.
- Liu T., Zhang L., Donghyun J., Sun S. (2017). *Signal Transduction and Targeted Therapy 2*. Published @017 July 14, NF-κB signaling in inflammation. DOI:10.1038/sigtrans.2017.23.
- Logadottir Y, Delbro D, Lindholm C, Fall M, Peeker R. Inflammation characteristics in bladder pain syndrome ESSIC type 3C/classic interstitial cystitis. *Int J Urol*. 2014 Apr;21 Suppl 1:75-8. doi: 10.1111/iju.12370. PMID: 24807505.
- Lotz M, Villiger P, Hugli T, Koziol J, Zuraw BL (1994). *Interleukin-6 and interstitial cystitis*. *J Urol*.
- Lu Y., Yeh W., Ohashi P.(2008). *LPS/TLR4 signal transduction pathway*, *Cytokine*. 2008 May;42(2):145-51, doi: 10.1016/j.cyto.2008.01.006.
- Ma Biao (2018). *Modular bioinformatics analysis demonstrates that a Toll-like receptor signaling pathway is involved in the regulation of macrophage polarization*. *Mol Med Rp*. 2018 Nov; 18(5): 4313-4320, doi: 10.3892/mmr.2018.9486.
- Maki, T., Kajioka, S., Itsumi, M., Kareman, E., Lee, K., Shiota, M., & Eto, M. (2019). Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle. *LUTS: Lower Urinary Tract Symptoms*. doi:10.1111/luts.12247
- Matsumoto M., Funami K., Oshiumi H., Seya T. (2013). *Toll-IL-1-receptor-containing adaptor molecule-1: a signaling adaptor linking innate immunity to adaptive immunity*. *Prog Mol Biol Transl Sci*. 2013;117:487-510, DOI: 10.1016/B978-0-12-386931-9.00018-0
- Mayoclinic (2020). TNFA - Clinical: Tumor Necrosis Factor (TNF), Plasma [Internet]. Mayo Clinic; Available from: <https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/63022>
- Micheal M, Parra S. (2008). *Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle*, *Naunyn Schmiedebergs Arch Pharmacol*. 2008 Aug;378(2):217-24, DOI: 10.1007/s00210-008-0316-5
- Mohkam M, Asgarian F, Fahimzad A, Sharifian M, Dalirani R, Gorgi FA (2009). *Diagnostic potential of urinary tumor necrosis factor-alpha in children with acute pyelonephritis*. *Iran J Kidney Dis*.
- Montana G., Lampiasi N. (2016). *Substance P Induces HO-1 Expression in RAW 264.7 Cells Promoting Switch towards M2-Like Macrophages*. *PLoS One*. 2016 Dec 1;11(12):e0167420, DOI: 10.1371/journal.pone.0167420

- Moore KW, Malefyt RdW, Coffman RL, O'Garra A. Interleukin-10 and the Interleukine-10 receptor. *Annu Rev Immunol.* 2001; 19: 683-765
- Moradi M, Abdi H, Ebrahimi S, Rezaee H, Kaseb K (2017). *Effects of Tamsulosin and Tolterodine on double J stent-related symptoms: A double-blind, randomized, plasebo-controlled trial.* SAGE Open Med [Internet]. [Updated 2017 Dec 28;5:205031211769643; cited 2021 Feb 10]. Available from: <http://journals.sagepub.com/doi/10.1177/2050312117696436>
- Mosser D.(2003). *The many faces of macrophage activation.* J Lukoc Biol. 2003 Feb;73(2):209-12, doi: 10.1189/jlb.0602325.
- Nachawati D, Patel J. Alpha Blockers. [Updated 2021 Jul 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK556066/>
- Navanimitkul N, Lojanapiwat B. Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: a randomized controlled study. *J Int Med Res.* 2010 Jul-Aug;38(4):1436-41. doi: 10.1177/147323001003800425. PMID: 20926016.
- Newton K., Dixit V. (2012). *Signaling in innate immunity and inflammation.* Cold Spring Harb Perspect Biol. 2012 Mar;4(3):a006049, doi: 10.1101/cshperspect.a006049.
- Noh, T. I., Shim, J. S., Kang, S. G., Kang, S. H., Cheon, J., & Lee, J. G. (2021). Effects of  $\beta$ 3-adrenoceptor agonist on acute urinary retention in a rat model. *World Journal of Urology*, 39(12), 4427–4433. <https://doi.org/10.1007/s00345-021-03774-7>
- O'Shea J., Paul W. (2010). *Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells.* *Science.* 2010 Feb 26;327(5969):1098-102, doi: 10.1126/science.1178334.
- Oeckinghaus A., Ghosh S. (2009). *The NF-kappaB family of transcription factors and its regulation,* Cold Spring Harb Perspect Biol 2009 Oct;1(4):a000034, DOI: 10.1101/cshperspect.a000034
- Otsuki H, Yamasaki T, Hori S, Aoki H, Kosaka T, Uehara S, (2020). *The Efficacy of Mirabegron for the Relief of Stent ureter-Related Symptoms.* Acta Med Okayama [Internet]. [Updated 2020 Apr;74(2):145–50; cited 2021 Jan 27]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32341589>
- Palinggi E, Palinrungi MA, Palinrungi A, Seweng A, Kholis K, Syahrir S, (2020). *Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS).* J Med Allied Sci. 2020;10(2):115.
- Pansota MS, Rasool M, Saleem MS, Tabassum SA (2013). *Indications and Complications of Double J Stent uretering : Our Experience.* Gomal J Med Sci.
- Parsons L, Boychuk D, Jones S, Hurst R, Callahan H. (1990). *Bladder Surface Glycosaminoglycans: An Epithelial Permeability Barrier.* J Urol [Internet]. [Updated 1990 Jan;143(1):139–42; cited 2021 Feb 10]. Available from: <http://www.jurology.com/doi/10.1016/S0022-5347%2817%2939897-X>
- Pérez A, Santamaria EK, Operario D, Tarkang EE, Zotor FB, Cardoso SR de SN, (2017). No 主観的健康感を中心とした在宅高齢者における健康関連指標に関する共分散構造分析Title. BMC

- Public Health [Internet]. [Updated 2017;5(1):1–8; cited 2021 Feb 10]. Available from: <https://ejournal.poltektegal.ac.id/index.php/siklus/article/view/298%0Ahttp://repositorio.unan.edu.ni/2986/1/5624.pdf%0Ahttp://dx.doi.org/10.1016/j.jana.2015.10.005%0Ahttp://www.biomedcentral.com/14712458/12/58%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&P>
- Pereira-Correia JA, Nahoum LA, Aldred Pinto JE, Fernandes Muller VJ (2021) Mirabegron to manage symptoms of interstitial cystitis / bladder pain syndrome: A stone for two birds? *Arch Urol Res* 5(1): 020-023. DOI: 10.17352/aur.000032
- Petes C, Mariani MK, Yang Y, Grandvaux N, Gee K (2018). *Interleukin (IL)-6 Inhibits IL-27- and IL-30-Mediated Inflammatory Responses in Human Monocytes*. *Front Immunol*. 2018;9:256. [Updated 2018 Feb 15; cited 2021 Feb 10]. doi:10.3389/fimmu.2018.00256
- Pillalamarri N, Shalom DF, Pilkinton ML, Winkler HA, Chatterjee PK, Solanki M, Metz CN. Inflammatory Urinary Cytokine Expression and Quality of Life in Patients With Overactive Bladder. *Female Pelvic Med Reconstr Surg*. 2018 Nov/Dec;24(6):449-453. doi: 10.1097/SPV.0000000000000492. PMID: 28953078.
- Pramana IBP, Oka AAG, Duarsa GWK, Santosa KB, Yudianta W, Tirtayasa PMW, et al. The effectiveness of tamsulosin in benign prostate hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS): a multi-centre cohort retrospective study. *Indonesia Journal of Biomedical Science* 2020;14 (1): p.17-20.
- Puel A, Casanova J-L (2019). *The nature of human IL-6*. *J Exp Med* [Internet]. [Updated 2019 Sep 2;216(9):1969–71; cited 2021 Feb 10]. Available from: [https://rupress.org/jem/article/216/9/1969/120719/The\\_nature\\_of\\_human\\_IL-6\\_The-nature-of-human-IL-6](https://rupress.org/jem/article/216/9/1969/120719/The_nature_of_human_IL-6_The-nature-of-human-IL-6)
- Puyo CA, Earhart A, Staten N, Huang Y, Desai A, Lai H, (2018). *Mitochondrial DNA induces Foley catheter related bladder inflammation via Toll-like receptor 9 activation*. *Sci Rep* [Internet]. [Update 2018 Dec 23;8(1):6377; cited 2021 Jan 27]. Available from: <http://www.nature.com/articles/s41598-018-24818-w>
- Ragab M, Soliman MG, Tawfik A, Abdel Raheem A, El-Tatawy H, Abo Farha M, (2017). *The role of pregabalin in relieving stent ureter-related symptoms: a randomized controlled clinical trial*. *Int Urol Nephrol* [Internet]. [Updated 2017 Jun 4;49(6):961–6; cited 2021 Jan 27]. Available from: <http://link.springer.com/10.1007/s11255-017-1561-7>
- Reicherz A, Eltit F, Scotland K, et al. Indwelling stents cause severe inflammation and fibrosis of the ureter via urothelial–mesenchymal transition. *Sci Rep* 13, 5492 (2023). <https://doi.org/10.1038/s41598-023-31885-1>
- Robinson, D. and Cardozo, L. (2009) ‘Solifenacin : pharmacology and clinical efficacy’, *Expert Review of Clinical Pharmacology*, 2(3), pp. 239–253. doi: 10.1586/ecp.09.3.
- Roilides E, Papachristou F, Gioulekas E, Tsaparidou S, Karatzas N, Sotiriou J, (2019). *Increased urine interleukin-6 concentrations correlate with pyelonephritic changes on 99mTc-dimercaptosuccinic*

- acid scans in neonates with urinary tract infections.* J Infect Dis. 1999.
- Rothstein T., Griffin D., Holodick N., Quach D., Kaku H. (2013). *Activation of B-1 Cells.* Ann N Y AcadSci. 2013 May;1285: 970114, DOI: 10.1016/B978-0-12-374279-7.09021-4
- Sacco E, Bientinesi R (2012). *Mirabegron: a review of recent data and its prospects in the management of overactive bladder.* Ther Adv Urol. 2012;4(6):315-324. doi:10.1177/1756287212457114
- Saraiva M, O'Garra A. The regulation of *IL-10* production by immune cells. Nat Rev Immunol 10, 170–181 (2010). <https://doi.org/10.1038/nri2711>
- Saraiva M, Vieira P, O'Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med 6 January 2020; 217 (1): e20190418. doi: <https://doi.org/10.1084/jem.20190418>
- Sawada, N., Nomiya, M., Hood, B., Koslov, D., Zarifpour, M., & Andersson, K.-E. (2013). Protective Effect of a  $\beta$ 3-Adrenoceptor Agonist on Bladder Function in a Rat Model of Chronic Bladder Ischemia. European Urology, 64(4), 664–671. doi:10.1016/j.eururo.2013.06.043
- Sung-Eun Kim, Jin-Hee Han, Il-Gyu Ko, Chang-Ju Kim & Khae Hawn Kim (2017) Alpha1-adrenergic receptor antagonist tamsulosin ameliorates aging-induced memory impairment by enhancing neurogenesis and suppressing apoptosis in the hippocampus of old-aged rats, Animal Cells and Systems, 21:6, 404-411, DOI: 10.1080/19768354.2017.1404492
- Scotland KB, Lo J, Grgic T, Lange D (2019). *Stent ureter-associated infection and sepsis: pathogenesis and prevention: a review.* Biofouling [Internet]. [Updated 2019 Jan 2;35(1):117–27; cited 2021 Jan 27]. Available from: <https://www.tandfonline.com/doi/full/10.1080/08927014.2018.1562549>
- Segarra-Medrano A, Carnicer-Caceres C, Valtierra-Carmeno N, Agraz-Pamplona I, Ramos-Terrades N, Jatem Escalante E, (2013). *Value of urinary levels of interleukin-6, epidermal growth factor, monocyte chemoattractant protein type1 and transforming growth factor  $\beta$ 1 in predicting the extent of fibrosis lesions in kidney biopsies of patients with IgA nephropathy.* Nefrologia [Internet]. [Updated 2013 Oct 37(5):531–8; cited 2021 Feb 10]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28946966>
- Senftleben U. (2001). *Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway.* Science. 2001 Aug 24;293(5534):1495-9, doi: 10.1126/science.1062677.
- Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther. 2017;11:463-467. Published 2017 Feb 20. doi:10.2147/DDDT.S101630
- Shen H, Kreisel D, Goldstein DR (2013). *Processes of Sterile Inflammation.* J Immunol [Internet]. [Updated 2013 Sep 15;191(6):2857–63; cited 2021 Jan 27]. Available from: <http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1301539>
- Sica A., Mantovani A. (2012). *Macrophage plasticity and polarization: in vivo veritas.* J Clin Invest. 2012 Mar 1; 122(3):787-95, doi: 10.1172/JCI59643.
- Sun L, Sun C, Zhou S, Zhang L, Hu W (2021) Tamsulosin attenuates high glucose- induced injury in glomerular endothelial cells. Bioengineered 12:5184– 5194
- Sun S., Ley S. (2008). *New insights into NF-kappaB regulation and function.* Trends Immunol. 2008

- Oct;29(10): 469-478, doi: 10.1016/j.it.2008.07.003.
- Sun S. (2010). *Non-canonical NF- $\kappa$ B signaling pathway*. Published: 2010 December 21, Cell Research 21,71-85(2011), DOI: 10.1038/cr.2010.177.
- Sun S. (2012). *The noncanonical NF- $\kappa$ B pathway*. Immunol Rev., 2012 Mar: 246(1): 125-140, doi: 10.1111/j.1600-065X.2011.01088.x.
- Sun S., Chang J., Jin J. (2013). *Regulation of nuclear factor- $\kappa$ B in autoimmunity*. Trends Immunol. 2013 Jun;34(6):282-9, doi: 10.1016/j.it.2013.01.004.
- Sundvall P-D, Elm M, Ulleryd P, Mölstad S, Rodhe N, Jonsson L, (2014). Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr [Internet]. [Updated 2014 Dec 12;14(1):88; 2021 Feb 10]. Available from: <http://bmcgeriatr.biomedcentral.com/articles/10.1186/1471-2318-14-88>
- Tae BS, Cho S, Jeon BJ, Choi H, Park JY, Cho SY, (2018). *Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study*. BJU Int [Internet]. [Updated 2018 Nov;122(5):866–72, cited 2021 Jan 27]. Available from: <http://doi.wiley.com/10.1111/bju.14416>
- Taguchi M., Yoshida K., Sugi M., Matsuda T., Kinoshita H., (2017). *A stent ureter crossing the bladder midline leads to worse urinary symptoms*. Cent Eur J Urol. Published online 2017 Nov 2017.
- Takeuchi O., Akira S. (2010). *Pattern recognition receptors and inflammation*, Cell Volume 140, Issue 6, 2010 March 19, P 805-20, DOI: 10.1016/j.cell.2010.01.022
- Takusagawa S, Van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, (2012). *Absorption, metabolism and excretion of [<sup>14</sup>C]mirabegron (YM178), a potent and selective  $\beta$  3-adrenoceptor agonist, after oral administration to healthy male volunteers*. Drug Metab Dispos. 2012;40(4):815–24.
- Todorova VB, Baxan N, Delahaye M, Harding SE, Rankin SM (2023) Drug- based mobilisation of mesenchymal stem/stromal cells improves cardiac function post myocardial infarction. Dis Model Mech 16:1–10
- Unver N., McAllister F (2018). *IL-6 Family Cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets*. Cytokine Growth Factor Rev. [Updated 2018 June; 41 : 10-17; cited 2021 Feb 10]. Doi:10.1016/j.cytogfr.2018.04.004
- Van Besien J, Keller EX, Somani B, Pietropaolo A, Claessens M, Merckx L, Tailly T, De Coninck V. *Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis*. Eur Urol Focus. 2022 Jul;8(4):1031-1041. doi: 10.1016/j.euf.2021.10.002. Epub 2021 Oct 20. PMID: 34688588.
- Vogt B, Chokri I. *Histological Inflammation in Human Ureter either Healthy or Fitted with Double-Pigtail Stent or a Thin 0.3 F Suture Thread: A Preliminary Study*. Adv. Urol. 2020. <https://doi.org/10.1155/2020/120489>

- Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy (2020). *Safety, and tolerability of mirabegron in patients aged  $\geq 65$  yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)*. Eur Urol [Internet]. [Updated 2020;77(2):211–20; cited 2021 Feb 10]. Available from: <https://doi.org/10.1016/j.eururo.2019.10.002>
- Wang J, Zhou Z, Cui Y, Li Y, Yuan H, Gao Z, (2019). *Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder*. NeuroUrol Urodyn. 2019;38(1):22–30.
- Wang N., Liang H., Zen K. (2014). *Molecular mechanisms that influence the macrophage m1-m2 polarization balance*. Front Immunol 2014;5:614, doi: 10.3389/fimmu.2014.00614.
- Warren, K., Burden, H., & Abrams, P. (2016). Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Therapeutic Advances in Drug Safety, 7(5), 204–216. doi:10.1177/2042098616659412 10.1177/2042098616659412
- Willis-Gray MG, Dieter AA, Geller EJ (2016). *Evaluation and management of overactive bladder: strategies for optimizing care*. Res Rep Urol. 2016;8:113-122. [Updated 2016 Jul 27; cited 2021 Feb 10]. doi:10.2147/RRU.S93636
- Wolff GF, Kuchel GA, Smith PP (2014). *Overactive bladder in the vulnerable elderly*. Res Rep Urol. 2014;6:131-138. [Updated 2014 Oct 3; cited 2021 Feb 10]. doi:10.2147/RRU.S41843
- Wood MW, Breitschwerdt EB, Gookin JL (2011). *Autocrine Effects of Interleukin-6 Mediate Acute-Phase Proinflammatory and Tissue-Reparative Transcriptional Responses of Canine Bladder Mucosa*. Bäumlér AJ, editor. Infect Immun [Internet]. [Updated 2011 Feb;79(2):708–15; cited 2021 Feb 10]. Available from: <https://iai.asm.org/content/79/2/708>
- Wu J, Ding Y, Zhu C, Shao X, Xie X, Lu K, (2013). *Urinary TNF- $\alpha$  and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes*. Exp Ther Med.
- Yan H, Wang Y, Sun R, Cui Y (2017). *The Efficacy of Antimuscarinics Alone or in Combination with Alpha-Blockers for the Treatment of Stent ureter-Related Symptoms: A Systematic Review and Meta-Analysis*. Urol Int [Internet]. [Updated 2017;99(1):6–13; cited 2021 Feb 10]. Available from: <https://www.karger.com/Article/FullText/449390>
- Yang L, Whiteside S, Cadieux PA, Denstedt JD (2015). *Stent ureter technology: Drug-eluting stents and stent coatings*. Asian J Urol [Internet]. [Updated 2015 Oct;2(4):194–201; cited 2021 Jan 27]. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2214388215000995>
- Yavuz A, Kilinc MF, Aydin M, Ofluoglu Y, Bayar G (2020). *Does tamsulosin or mirabegron improve stent ureter-related symptoms? A prospective placebo-controlled study*. LUTS Low Urine Tract Symptoms [Internet]. [Updated 2020 May 14;luts.12320; cited 2021 Feb 10]. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/luts.12320>
- Ye Y, Xu Q, Wan M (2021) Tamsulosin combined with levofloxacin can effectively improve the clinical symptoms and reduce inflammation in CP/CPPS patients. Int J Clin Exp Med 14:326–332

- Yuan Q. (2021). *MyD88 in myofibroblasts enhances colitis-associated tumorigenesis via promoting macrophage M2 polarization*. Cell Reports Volume 34, Issue 5, 2021 February 2, 108724, DOI: 10.1016/j.celrep.2021.108724.
- Zhang H., Sun S (2015). *NF- $\kappa$ B in inflammation and renal diseases*. Published online 2015 Nov 16, Cell Biosci. 1015;5:63, doi: 10.1186/s13578-015-0056-4
- Zhang Y, Chu P, Wang W (2017). *PRISMA-combined  $\alpha$ -blockers and antimuscarinics for stent ureter-related symptoms*. Medicine (Baltimore) [Internet]. [Updated 2017 Feb;96(7):e6098; cited 2021 Feb 10]. Available from: <http://journals.lww.com/00005792-201702170-00026>.
- Zheng Z, Zhang J, Zhang C, Li W, Ma K, Huang H, Li K, Yao Y. The study on the function and cell source of interleukin-6 in interstitial cystitis/bladder painful syndrome rat model. Immun Inflamm Dis. 2021 Dec;9(4):1520-1528. doi: 10.1002/iid3.505. Epub 2021 Aug 18. PMID: 34407316; PMCID: PMC8589393.
- Zhou L, Cai X, Li H, Wang K (2015). *Effects of  $\alpha$ -Blockers, Antimuscarinics, or Combination Therapy in Relieving Stent ureter-Related Symptoms: A Meta-Analysis*. J Endourol [Internet]. [Updated 2015 Jun;29(6):650–6; cited 2021 Feb 10]. Available from: <http://www.liebertpub.com/doi/10.1089/end.2014.0715>

## LAMPIRAN

### URETERIC STENT SYMPTOMS QUESTIONNAIRE

#### Questionnaire 1 (Stent in situ)

J double ureteral kateter telah dimasukkan. Kami ingin mengetahui pendapat Anda tentang beberapa aspek yang berkaitan dengan kesehatan Anda setelah memasukkan kateter.

Silakan isi bagian-bagian berbeda dari kuesioner yang akan Anda temukan di bawah ini.

Jawab semua pertanyaan di setiap bagian.

(Kami akan sangat menghargai jika Anda mengisi kuesioner dan mengirimkannya kepada kami dalam tujuh hari)

Tanggal hari ini       --/--/----

Tanggal lahir         --/--/----

Pada beberapa kesempatan Anda ditanya apakah Anda memiliki gejala sesekali, kadang-kadang, atau sebagian besar waktu.

Sekali-sekali maksudnya adalah kurang dari sepertiga waktu. Jawaban Terkadang itu berarti antara satu dan dua pertiga waktu. Sebagian besar waktu itu berarti lebih dari dua pertiga waktu (dalam sehari).

#### URINARY SYMPTOMS

Kami meminta Anda untuk menjawab pertanyaan dengan memikirkan ketidaknyamanan berkemih yang Anda derita setelah pemasangan kateter ureter.

Harap tandai hanya satu jawaban (kotak) untuk setiap pertanyaan.

Pikirkan hanya tentang pengalaman Anda setelah pemasangan kateter.

U1. Pada siang hari, seberapa sering Anda buang air kecil?

- Lebih dari sekali dalam satu jam
- Setiap jam
- Setiap dua jam
- Setiap tiga jam
- Setiap empat jam atau lebih

U2. Pada malam hari, seberapa sering Anda harus bangun untuk buang air kecil?

- Tidak pernah
- Sekali
- Dua kali
- Tiga kali
- Empat kali atau lebih



- U3. Apakah Anda harus lari ke toilet untuk buang air kecil?
- Tidak pernah
  - Sekali-sekali (kurang dari sepertiga waktu)
  - Terkadang (antara satu dan dua pertiga waktu)
  - Sebagian besar waktu (lebih dari dua pertiga waktu)
  - Selalu
- U4. Apakah Anda mengalami urin mengalir sebelum sampai ke toilet?
- Tidak pernah
  - Sekali-sekali (kurang dari sepertiga waktu)
  - Terkadang (antara satu dan dua pertiga waktu)
  - Sebagian besar waktu (lebih dari dua pertiga waktu)
  - Selalu
- U5. Apakah urin Anda keluar tanpa disadari sehingga Anda BAK sebelum berada di toilet?
- Tidak pernah
  - Sekali-sekali (kurang dari sepertiga waktu)
  - Terkadang (antara satu dan dua pertiga waktu)
  - Sebagian besar waktu (lebih dari dua pertiga waktu)
  - Selalu
- U6. Seberapa sering Anda merasa bahwa kandung kemih belum sepenuhnya kosong setelah buang air kecil?
- Tidak pernah
  - Sekali-sekali (kurang dari sepertiga waktu)
  - Terkadang (antara satu dan dua pertiga waktu)
  - Sebagian besar waktu (lebih dari dua pertiga waktu)
  - Selalu
- U7. Apakah Anda memiliki sensasi menyengat saat buang air kecil?
- Tidak pernah
  - Sekali-sekali (kurang dari sepertiga waktu)
  - Terkadang (antara satu dan dua pertiga waktu)
  - Sebagian besar waktu (lebih dari dua pertiga waktu)
  - Selalu
- U8. Berapa kali Anda mengamati darah dalam urin Anda?
- Tidak pernah
  - Sekali-sekali (kurang dari sepertiga waktu)
  - Terkadang (antara satu dan dua pertiga waktu)
  - Sebagian besar waktu (lebih dari dua pertiga waktu)
  - Selalu
- U9. Berapa banyak darah yang Anda perhatikan dalam urin Anda?
- Saya tidak pernah melihat darah
  - Urin sedikit bernoda darah
  - Air seni sangat ternoda darah
  - Urin berwarna darah dan disertai gumpalan
- U10. Secara umum, sejauh mana gejala kencing Anda menjadi masalah bagi Anda?
- Tidak ada
  - Sedikit
  - Sedang
  - Cukup
  - Banyak
- U11. Jika Anda harus menghabiskan sisa hidup Anda dengan gejala-gejala yang terkait dengan kateter, seperti sekarang, bagaimana perasaan Anda?
- Sangat bahagia
  - Senang
  - Cukup puas
  - Biasa saja
  - Cukup tidak puas

- Tidak puas
- Sangat tidak bahagia

**NYERI PADA TUBUH (UNTUK PRIA)**


Pada bagian ini Anda akan menemukan pertanyaan terkait dengan rasa sakit atau ketidaknyamanan yang Anda kaitkan dengan penempatan kateter ureter.

Pikirkan pengalaman Anda setelah memasukkan kateter.

P1. Pernahkah Anda menderita jenis rasa sakit atau ketidaknyamanan terkait dengan keberadaan kateter ureter?

- Ya (lanjut ke pertanyaan P2)
- Tidak (buka bagian selanjutnya, abaikan pertanyaan dari P2 hingga P9)

P2. Bayangkan gambar di bawah ini adalah representasi tubuh Anda. Tandai dengan tanda X atau warnai tempat di mana Anda merasa sakit atau tidak nyaman terkait dengan kateter (misalnya, selama aktivitas sehari-hari atau setiap kali buang air kecil):



- A: Wilayah ginjal depan / lateral
- B: Wilayah Inguinal
- C: Wilayah kandung kemih
- D: Penis
- E: Wilayah ginjal lumbar (area belakang)

Dalam hal menderita sakit di lebih dari satu titik, tunjukkan lokasi masing-masing.

P3. Pada skala 0 hingga 10, tandai dengan X titik yang menunjukkan intensitas rasa sakit atau ketidaknyamanan Anda terkait dengan kateter. Jika Anda merasa sakit atau tidak nyaman di lebih dari satu tempat, beri tanda sebanyak mungkin dan tulis di sebelahnya huruf yang sesuai dengan setiap lokasi.

Tidak merasa sakit 0 1 2 3 4 5 6 7 8 9 10 Rasa sakit yang sangat intens atau ketidaknyamanan

**NYERI PADA TUBUH (UNTUK WANITA)**


Pada bagian ini Anda akan menemukan pertanyaan terkait dengan rasa sakit atau ketidaknyamanan yang Anda kaitkan dengan penempatan kateter ureter.

Tolong pikirkan pengalaman Anda setelah memasukkan kateter.

P1. Pernahkah Anda menderita jenis rasa sakit atau ketidaknyamanan terkait dengan keberadaan kateter ureter?

- Ya (lanjut ke pertanyaan P2)
- Tidak (buka bagian selanjutnya, abaikan pertanyaan dari P2 hingga P9)

P2. Bayangkan bahwa gambar di bawah ini adalah representasi tubuh Anda, tandai dengan X atau warnai tempat-tempat di mana Anda merasa sakit atau tidak nyaman terkait dengan kateter (misalnya, selama kegiatan sehari-hari atau setiap kali Anda buang air kecil) :



A: daerah ginjal frontal / lateral

B: Wilayah Inguinal

C: Wilayah kandung kemih

D: Wilayah ginjal lumbar (area belakang)

Dalam hal menderita sakit di lebih dari satu titik, tunjukkan lokasi masing-masing.

P3. Pada skala 0 hingga 10, tandai dengan X titik yang menunjukkan intensitas rasa sakit atau ketidaknyamanan Anda terkait dengan kateter. Jika Anda merasa sakit atau tidak nyaman di lebih dari satu tempat, beri tanda sebanyak mungkin dan tulis di sebelahnya huruf yang sesuai dengan setiap lokasi.

Tidak merasa sakit 0 1 2 3 4 5 6 7 8 9 10 Rasa sakit yang sangat intens atau ketidaknyamanan

P4. Manakah dari pernyataan berikut yang paling menggambarkan situasi Anda mengenai aktivitas fisik dan rasa sakit atau ketidaknyamanan terkait dengan keberadaan kateter?

- Saya tidak merasakan sakit atau tidak nyaman
- Saya mengalami rasa sakit atau ketidaknyamanan hanya ketika saya melakukan aktivitas fisik yang intens (misalnya, olahraga intens atau mengangkat benda berat)
- Saya merasakan sakit atau tidak nyaman ketika melakukan aktivitas dengan intensitas sedang tetapi tidak dalam aktivitas sederhana (misalnya berjalan beberapa ratus meter atau mengendarai mobil)
- Saya merasakan sakit bahkan ketika saya melakukan kegiatan dasar kehidupan sehari-hari (misalnya, berjalan di sekitar rumah atau berpakaian)
- Saya merasa sakit saat istirahat

P5. Apakah Anda bangun di malam hari karena sakit atau tidak nyaman terkait dengan kateter?

- Tidak pernah
- Sekali-sekali (kurang dari sepertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Selalu

P6. Apakah Anda merasakan sakit atau tidak nyaman terkait dengan kateter saat buang air kecil?

- Tidak pernah
- Sekali-sekali (kurang dari sepertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Selalu

P7. Apakah Anda merasakan sakit atau tidak nyaman di area ginjal saat buang air kecil?

- Tidak
- Ya

P8. Berapa kali Anda perlu menggunakan analgesik (penghilang rasa sakit) untuk mengontrol rasa sakit atau ketidaknyamanan yang terkait dengan kateter?

- Tidak pernah
- Sekali-sekali (kurang dari sepertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Selalu

P9. Secara umum, sejauh mana rasa sakit atau ketidaknyamanan yang terkait dengan kateter mempengaruhi kehidupan sehari-hari Anda?

- Tidak ada

- Sedikit
- Sedang
- Cukup
- Banyak

### **STATUS KESEHATAN UMUM**

Bagian ini menyelidiki kesehatan umum Anda setelah pemasangan kateter ureter.

G1. Pernahkah Anda mengalami kesulitan melakukan aktivitas fisik ringan (misalnya berjalan jarak pendek atau mengemudi mobil)?

- Biasanya tanpa kesulitan
- Umumnya dengan beberapa kesulitan
- Umumnya dengan banyak kesulitan
- Saya biasanya tidak melakukannya karena kateter
- Selalu

G2. Pernahkah Anda mengalami kesulitan dalam melakukan aktivitas fisik yang intens (misalnya, olahraga intens atau mengangkat benda berat)?

- Biasanya tanpa kesulitan
- Umumnya dengan beberapa kesulitan
- Umumnya dengan banyak kesulitan
- Saya biasanya tidak melakukannya karena kateter
- Selalu

G3. Apakah Anda merasa lelah tanpa kegiatan fisik?

- Tidak pernah
- Sekali-sekali (kurang dari sepertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Selalu

G4. Pernahkah anda merasa tenang?

- Selalu
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sekali-sekali (kurang dari sepertiga waktu)
- Tidak pernah

G5. Apakah Anda menikmati kehidupan sosial Anda (misalnya, pergi keluar, mengundang teman ke rumah, dll.)?

- Selalu
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sekali-sekali (kurang dari sepertiga waktu)
- Tidak pernah

G6. Apakah Anda membutuhkan lebih banyak bantuan dari biasanya dari keluarga atau teman?

- Tidak pernah
- Sekali-sekali (kurang dari sepertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Selalu

### **AKTIVITAS KERJA**

W1. Tentukan status pekerjaan Anda

- Pekerjaan penuh waktu
- Kerja paruh waktu
- Pensiun karena sakit
- Siswa
- Menganggur atau mencari pekerjaan
- Pensiun karena alasan lain (termasuk berdasarkan usia)
- Saya tidak bekerja karena alasan berikut (sebutkan mana) .....

W2 Setelah pemasangan kateter, berapa hari Anda harus tetap di tempat tidur sepanjang hari atau sebagian karena gejala yang terkait dengan kateter? Jumlah hari ...

W3 Setelah pemasangan kateter, berapa hari Anda harus mengurangi aktivitas harian karena gejalanya?  
Jumlah hari ...

Jawab pertanyaan berikut (W4-W7) hanya jika Anda memiliki pekerjaan berbayar

- W4 a) Posisi profesional dan deskripsi pekerjaan Anda: .....  
b) Anda adalah: karyawan  
Wiraswasta  
Pengusaha

Jawab pertanyaan-pertanyaan berikut hanya jika Anda telah bekerja setelah pemasangan kateter

W5. Apakah Anda pernah bekerja dalam waktu singkat atau memerlukan cuti sakit sehari-hari karena gejala yang terkait dengan kateter?

- Tidak pernah
- Sekali-sekali (kurang dari sepertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Selalu

W6. Apakah Anda perlu melakukan perubahan pada pekerjaan yang biasa anda lakukan karena gejala yang terkait dengan kateter?

- Tidak pernah
- Sekali-sekali (kurang dari sepertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Selalu

W7 Sudahkah Anda bekerja dengan jumlah jam yang biasa?

- Tidak pernah
- Sekali-sekali (kurang dari sepertiga waktu)
- Terkadang (antara satu dan dua pertiga waktu)
- Sebagian besar waktu (lebih dari dua pertiga waktu)
- Selalu

#### **MASALAH SEKSUAL**

Harap tandai satu kotak untuk setiap pertanyaan dengan mempertimbangkan pengalaman Anda setelah memasukkan kateter.

S1. Saat ini, apakah Anda memiliki kehidupan seks yang aktif?

- Tidak (lanjut ke pertanyaan S2 dan langsung ke bagian selanjutnya)
- Ya (lanjut ke pertanyaan S3)

S2. Jika Anda tidak memiliki kehidupan seks yang aktif, sejak kapan itu terjadi pada Anda?

- Sejak penempatan kateter ureter
- Sebelum penempatan kateter ureter

Mengapa kegiatan seksual anda menjadi tidak aktif/ terputus saat ini?

- Karena masalah yang terkait dengan kateter ureter
- Saya belum mencoba melakukan aktivitas seksual
- Untuk alasan lain yang tidak terkait dengan kateter

Jawab pertanyaan S3 dan S4 hanya jika Anda menjawab "ya" untuk pertanyaan S1. Pertanyaan-pertanyaan ini merujuk pada kehidupan seks Anda setelah penempatan kateter.

S3. Apakah Anda pernah merasakan sakit saat berhubungan seks? Jika ya, jenis apa?

- Tidak
- Ringan
- Sedang
- Kuat
- Sangat kuat

S4. Apakah Anda puas dengan kehidupan seks Anda?

- Sangat puas

- Puas
- Tidak terlalu puas
- Tidak puas
- Sangat tidak puas

**KETIDAKNYAMANAN LAINNYA**

Pertanyaan-pertanyaan yang Anda temukan di bawah ini berfokus pada pengalaman Anda setelah pemasangan kateter ureter. Harap tunjukkan pengalaman Anda dengan menandai kotak yang sesuai dengan tanda X.

A1. Seberapa seringkah Anda mengira bahwa Anda menderita infeksi urin (demam terus menerus, lemas, atau nyeri saat buang air kecil)?

- Tidak pernah
- Sekali-sekali
- Terkadang
- Sering
- Selalu

A2. Apakah Anda perlu minum antibiotik disebabkan karena penempatan kateter (tidak termasuk antibiotik preventif yang Anda minum sebelum penempatan kateter).

- Tidak pernah
- 1 putaran
- 2 putaran
- 3 putaran atau lebih

A3. Apakah Anda memerlukan bantuan dokter atau perawat untuk masalah apa pun yang terkait dengan kateter?

- Tidak pernah
- 1 kali
- 2 kali
- 3 kali atau lebih

A4. Apakah Anda perlu pergi ke rumah sakit untuk masalah yang terkait dengan kateter?

- Tidak pernah
- 1 kali
- 2 kali
- 3 kali atau lebih

A5. Di masa mendatang, jika saya harus mengambil kateter ureter lagi, bagaimana rasanya?

- Sangat bahagia
- Senang
- Cukup puas
- Biasa saja
- Cukup tidak puas
- Tidak puas
- Sangat tidak bahagia

## **LAMPIRAN DAFTAR RIWAYAT HIDUP**

### **DATA PRIBADI**

Nama : Muhammad Asykar Ansharullah Palinrungi  
Tempat Lahir : Makassar, Sulawesi Selatan  
Tanggal Lahir : 14 Desember 1974  
Jenis Kelamin : Laki-laki  
Alamat Rumah : Jalan Batua Raya 9, Perum Griya Batara Permasi Blok A no 3, Makassar  
Alamat Instansi : Jalan Perintis kemerdekaan KM 11, RSUH Gedung A Lt 3  
Email : apalinrungi@yahoo.com

### **LATAR BELAKANG PENDIDIKAN**

	Tahun
• S3 Ilmu Kedokteran, Fakultas Kedokteran, Universitas Hasanuddin, Makassar	2018 – saat ini
• Konsultan Urologi Anak, Kolegium Urologi Indonesia	2020
• Program Pendidikan Spesialis Urologi, FK Universitas Indonesia, Jakarta	2005 – 2009
• Program Pendidikan Spesialis Ilmu Bedah, FK Universitas Hasanuddin, Makassar	2003 – 2005
• Program Studi Profesi Dokter, Fakultas Kedokteran Universitas Muslim Indonesia, Makassar	1999 – 2002
• S1 Ilmu Kedokteran, Fakultas Kedokteran Universitas Muslim Indonesia, Makassar	1992 – 1999
• SMAN 1 Makassar	1989 – 1992
• SMPN 7 Makassar	1986 – 1989
• SDN Pembangunan III, Makassar	1980 - 1986

### **RIWAYAT PEKERJAAN**

	Tahun
• Urolog dan Konsultan Pediatri Urologi, RS Dr. Wahidin Sudirohusodo Makassar	2022 – Saat ini
• Konsultan Pediatri Urologi, RSPTN Unhas, Makassar	2009 – Saat ini
• Ketua Divisi Urologi, Departemen Bedah, FK Unhas, Makassar	2015 – Saat ini
• Staf Pengajar Departemen Bedah, FK Unhas, Makassar	2009 – Saat ini
• Staf KSM Urologi, RSPTN Unhas, Makassar	2009 – Saat ini
• Staf Pengajar Departemen Bedah, FK Unismuh Makassar	2009 – 2018
• Staf Pengajar Departemen Bedah, FK Universitas Al-Khaerat, Palu, Sulteng	2009 – 2016
• Staf Pengajar departemen Bedah, FK Universitas Haluouleo, Kendari, Sultra	2009 – 2016

- |   |             |
|---|-------------|
| • Staf Pengajar Fakultas Ilmu Keolahragaan, Univ. Negeri Makassar, Makassar | 2002 – 2015 |
| • Staf KSM Urologi, RSUP Dr Wahidin Sudirohusodo, Makassar                  | 2009 – 2014 |
| • Staf Pengajar Departemen Bedah, FK UMI, Makassar                          | 2009 – 2014 |
| • Staf Pengajar Departemen Bedah, FK Univ. Nusa Cendana, Kupang             | 2009 – 2014 |
| • Staf Pengajar Departemen Bedah, FK Univ. Muhammadiyah Jakarta, Jakarta    | 2009 – 2011 |

### **ORGANISASI PROFESI**

- |   | Tahun           |
|---|-----------------|
| • Anggota International Continence Society (ICS)                  | 2022 – Saat ini |
| • Anggota Hyposphadia International Society (HIS)                 | 2021 – Saat ini |
| • Anggota Asia Pacific Association of Paediatric Urology (APAPU)  | 2019 – Saat ini |
| • Anggota Urological Association of Asia (UAA)                    | 2018 – Saat ini |
| • Anggota International Society of Reconstructive Urology (ISORU) | 2018 – Saat ini |
| • Anggota Societe Internationale D’Urologie (SIU)                 | 2015 – Saat ini |
| • Anggota Ikatan Ahli Urologi Indonesia (IAUI)                    | 2009 – Saat ini |
| • Anggota Ikatan Ahli Bedah Indonesia (IKABI)                     | 2009 – Saat ini |
| • Anggota Ikatan Dokter Indonesia (IDI)                           | 2002 - Saat ini |

### **INVITED LECTURER**

- |  | Tahun |
|--|-------|
| • Pertemuan Ilmiah Tahunan/ Continuing Medical Education ke 4, FK- UMI, Makassar   | 2022  |
| • Pertemuan Ilmiah Tahunan/ Annual Scientific Meeting of the Indonesian Urological Association (ASMIUA) ke 45, Ikatan Ahli Urologi Indonesia, Makassar | 2022  |
| • Webinar Sirkumsisi, Indonesian Society of Paediatric Urology (InaSPU), Ikatan Ahli Urologi Indonesia   | 2022  |
| • Virtual - Annual Scientific Meeting of Indonesian Urological Association. (ASMIUA) ke 43, Webinar  | 2020  |
| • Pertemuan Ilmiah Tahunan/ Continuing Medical Education, ke 20, FK Unhas, Makassar, Indonesia   | 2018  |
| • PCS World Congress of Urology ke 3, Athens, Greece   | 2017  |
| • Pertemuan Ilmiah Tahunan/ Continuing Medical Education ke 2, FK UMI Makassar, Indonesia  | 2017  |
| • Pertemuan Ilmiah Tahunan/ Annual scientific meeting of the Indonesian urological association (ASMIUA) ke 39, Surabaya, Indonesia                     | 2016  |
| • PCS World Congress of Urology ke 2, Marrakesh, Morocco   | 2016  |



- |   |      |
|---|------|
| • Pertemuan Ilmiah Tahunan/ Continuing Medical Education pertama, FK UMI, Makassar, Indonesia                                   | 2016 |
| • The Urological Asian Association Congress ke 13, Shanghai, China  | 2015 |
| • Pertemuan Ilmiah Tahunan/ Continuing Medical Education ke 18, FK Unhas, Makassar, Indonesia                                   | 2014 |
| • Trigonum Plus, Ikatan Ahli Bedah Indonesia, Makassar, Indonesia   | 2011 |
| • Pertemuan Ilmiah Tahunan/ Continuing Medical Education ke 16, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia | 2010 |

### PRESENTASI KARYA ILMIAH

- |   |                   |
|---|-------------------|
| • Undescended Testis: Characteristics and Management in Makassar, Indonesia<br><b>MA Palinrungi</b><br>The 22 <sup>nd</sup> Annual Congress of Asia-Pacific Association of Paediatric Urology, Seoul, South Korea   | Tahun<br>Oct 2022 |
| • Efficacy of Mirabegron, Solifenacin, Tamsulosin, Tadalafil, and their combination, in the Treatment of Double-J stent-Related Lower Urinary Tract Symptoms; a Prospective Randomized Trial.<br><b>MA Palinrungi</b> , H Rasyid, H Cangara, P Prihantono, A Bukhari.<br>The 52 <sup>nd</sup> Annual Meeting of the International Continence Society, Vienna, Austria | Sept 2022         |
| • Inconspicuous Penis: Buried, Webbed, Trapped, Megapreputium.<br><b>MA Palinrungi</b><br>The 44 <sup>th</sup> Annual Scientific Meeting of the Indonesian Urological Association, Makassar, Indonesia  | Sept 2022         |
| • Prevent and treat complications from circumcision<br><b>MA Palinrungi</b><br>Webinar Circumcision, Indonesian Society of Paediatric Urology (InaSPU), Indonesian Urological Association   | Feb 2022          |
| • Metanephric Adenoma of the kidney: case series<br>AA Mubarak, S Syarif, <b>MA Palinrungi</b> , A Azis, B Nelwan.<br>The 43 <sup>rd</sup> Virtual-Annual scientific meeting of the Indonesian Urological Association   | Dec 2020          |
| • Urinary tract stone in children: Diagnosis and Management.<br><b>MA Palinrungi</b><br>The 18 <sup>th</sup> Urological Association of Asia Congress (Virtual), Seoul, South Korea  | Oct 2020          |
| • Management of high-grade pediatric blunt renal trauma.<br><b>MA Palinrungi</b><br>The 21 <sup>st</sup> Asia Pacific Association of Pediatric Urology (APAPU), Perth, Australia  | Nov 2019          |
| • A Study of undescended testis in Makassar, Indonesia.<br>JF Oktarian, S Syahrir, <b>MA Palinrungi</b> .   | Aug 2019          |

<p>The 17th Urological Association of Asia Congress, Kuala Lumpur, Malaysia</p> <ul style="list-style-type: none"> <li>• Renal trauma, five years evaluation in Makassar, Indonesia. R Sunggiardi, S Bakri, <b>MA Palinrungi.</b> The 17th Urological Association of Asia Congress, Kuala Lumpur, Malaysia</li> </ul>	Aug 2019
<ul style="list-style-type: none"> <li>• Pediatric blunt renal trauma: a retrospective review from a single institution, five years of experience. <b>MA Palinrungi,</b> The 17th Urological Association of Asia Congress, Kuala Lumpur, Malaysia</li> </ul>	Aug 2019
<ul style="list-style-type: none"> <li>• First case report of an Adrenocortical carcinoma with ileal metastasis. MS Ramadhan, <b>MA Palinrungi,</b> WN Aisyah. Urofair - Singapore Urological Association. Singapore</li> </ul>	Apr 2019
<ul style="list-style-type: none"> <li>• Giant paravertebral ganglioneuroma Saat inied with scoliosis in adolescence- a case report. Putra, <b>MA Palinrungi,</b> Urofair – Singapore Urological Association. Singapore,</li> </ul>	Apr 2019
<ul style="list-style-type: none"> <li>• Malignant hemangiopericytoma renal: a case report. S Winoto, <b>MA Palinrungi,</b> K Kholis. The 10<sup>th</sup> Uro-Oncology Update, Solo, Indonesia</li> </ul>	Feb 2019
<ul style="list-style-type: none"> <li>• Renal Ewing’s sarcoma: a case report. R Sadly, <b>MA Palinrungi.</b> The 10<sup>th</sup> Uro-Oncology Update, Solo, Indonesia</li> </ul>	Feb 2019
<ul style="list-style-type: none"> <li>• Characteristic of Renal cell carcinoma in Makassar between 2009 – 2018. JF Oktorian, <b>MA Palinrungi.</b> The 10<sup>th</sup> Uro-Oncology Update, Solo, Indonesia</li> </ul>	Feb 2019
<ul style="list-style-type: none"> <li>• Simultaneous Penopubic Inverted V-Y Plasty and Creating New Penoscrotal Junction for Penile Lengthening after Partial Penectomy for Penile Carcinoma. <b>MA Palinrungi.</b> The 16<sup>th</sup> Urological Asian Association Congress, Kyoto, Japan</li> </ul>	Apr 2018
<ul style="list-style-type: none"> <li>• Prostate Cancer: Diagnostic and Management. <b>MA Palinrungi.</b> The XX Continuing Medical Education, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia</li> </ul>	Jan 2018
<ul style="list-style-type: none"> <li>• Comparison between Femoral Traction and Abdominal Traction of Urethral Catheter after TUR of the Prostate. <b>MA Palinrungi.</b> The PCS 3<sup>rd</sup> World Congress of Urology, Athena, Greece</li> </ul>	Nov 2017
<ul style="list-style-type: none"> <li>• Prostate Cancer: Makassar perspective. <b>MA Palinrungi.</b> The 2<sup>nd</sup> Continuing Medical Education, Division of Urology, Department of Surgery, Faculty of Medicine, Hasanuddin</li> </ul>	Nov 2017

- |   |           |
|---|-----------|
| University/ The 1 <sup>st</sup> Indonesian Urological Association Chapter Makassar Symposia, All About Prostate, Makassar, Indonesia  |           |
| • Mesonephric carcinoma: Case report and literature review.<br><b>MA Palinrungi</b> , S Syahrir, K Kholis, G Arsyadi.<br>The 15 <sup>th</sup> Urological Association of Asia Congress, Hongkong   | Aug 2017  |
| • Prostate Tuberculosis: Case report and literature review.<br><b>MA Palinrungi</b> , S Syahrir, K Kholis, G Arsyadi.<br>The 15 <sup>th</sup> Urological Association of Asia Congress, Hongkong   | Aug 2017  |
| • Penile paraffinoma: Why they do it, how we treat it.<br><b>MA Palinrungi</b> , S Syahrir.<br>The 15 <sup>th</sup> Urological Association of Asia Congress, Hongkong   | Aug 2017  |
| • Hubungan antara volume prostat dengan tingkat LUTS pada penderita pembesaran prostat jinak berdasarkan international prostate symptomsscore (IPSS) dan visual prostate symptomsscore (VPSS) di Makassar. <b>(Best Poster Award)</b><br>R Masyita, AM Palinrungi, <b>MA Palinrungi</b> , IJ Ganda.<br>Annual Meeting of Indonesian Association of Surgeons, Jogjakarta | May 2017  |
| • Urethral Stricture: Makassar perspective.<br><b>MA Palinrungi</b> .<br>The 39 <sup>th</sup> Annual scientific meeting of the Indonesian Urological Association (ASMIUA), Surabaya, Indonesia  | Dec 2016  |
| • Risk Factors of Late Hyponatremia after Transurethral Resection of the Prostate: Monitoring Electrolyte Post-Operative.<br><b>MA Palinrungi</b> .<br>The PCS 2 <sup>nd</sup> World Congress of Urology, Marrakesh, Morocco  | Nov 2016  |
| • Penile paraffinoma.<br><b>MA Palinrungi</b> .<br>The PCS 2 <sup>nd</sup> World Congress of Urology, Marrakesh, Morocco  | Nov 2016  |
| • Renal cell carcinoma: Seven years experience in Makassar, Indonesia.<br><b>MA Palinrungi</b> .<br>The 14 <sup>th</sup> Urological Association of Asia Congress, Singapore   | July 2016 |
| • Solitary neurofibroma adrenal gland: 1 <sup>st</sup> report from Indonesia.<br><b>MA Palinrungi</b> .<br>The 14 <sup>th</sup> Urological Association of Asia Congress, Singapore  | July 2016 |
| • Renal clear cell carcinoma risk factors related to Fuhrman's grading – comparison between young and elderly patients.<br>ZE Mandar, <b>MA Palinrungi</b> .<br>The 7 <sup>th</sup> Urology Oncology Jakarta update. Jakarta, Indonesia   | Feb 2016  |
| • Profile and characteristics of bladder cancer in Makassar 2010 – 2014.<br>E Krahmady, <b>MA Palinrungi</b> .<br>The 7 <sup>th</sup> Urology Oncology Jakarta update. Jakarta, Indonesia   | Feb 2016  |
| • Profile and characteristics of prostate cancer in south Sulawesi.<br>K Nur, <b>MA Palinrungi</b> .  | Feb 2016  |

<p>The 7<sup>th</sup> Urology Oncology Jakarta update. Jakarta, Indonesia</p> <ul style="list-style-type: none"> <li>• External validation of the Indonesian Prostate Cancer Risk Calculator (IPCRC) and comparison with PCPT, ERSPC, and KPCPC in an Indonesia cohort. F Abshari, P Yuri, G Wangge, ITWHS Adistra, NE Perdana, E Hadibrata, CDK Wijaya, C Tansil, A Tigor, F Safriadi, D Kadar, SM Warli, S Rochadi, R Danarto, L Hakim, W Djatisoesanto, S Hardjowijoto, <b>MA Palinrungi</b>, CA Mochtar, R Umbas, ARAH Hamid.</li> </ul>	Feb 2016
<p>The 7<sup>th</sup> Urology Oncology Jakarta update. Jakarta, Indonesia</p> <ul style="list-style-type: none"> <li>• Correlation between testosterone and aging male symptoms(AMS) score in Makassar. JD Laly, <b>MA Palinrungi</b>, AM Palinrungi.</li> </ul>	Oct 2015
<p>The 38<sup>th</sup> Annual scientific meeting Indonesian urological association (ASMIUA), Bali, Indonesia</p> <ul style="list-style-type: none"> <li>• Incidentally found intra-renal teratoma: Case report and review of literature. <b>MA Palinrungi.</b></li> </ul>	Sept 2015
<p>The 13<sup>th</sup> Urological Association of Asia Congress. Shanghai, China</p> <ul style="list-style-type: none"> <li>• Metanephric Adenoma: Case Report and review of literature. <b>MA Palinrungi.</b></li> </ul>	Sept 2015
<p>The 13<sup>th</sup> Urological Association of Asia Congress. Shanghai, China</p> <ul style="list-style-type: none"> <li>• Risk factors of late hyponatremia after transurethral resection of the prostate on benign prostate hypertrophy patient. <b>MA Palinrungi M.A.</b></li> </ul>	Sept 2015
<p>The 13th Urological Association of Asia Congress. Shanghai, China</p> <ul style="list-style-type: none"> <li>• Tatalaksana terkini pembesaran prostat jinak. <b>MA Palinrungi.</b></li> </ul>	2014
<p>Continuing Medical Education, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia</p> <ul style="list-style-type: none"> <li>• Kelainan kongenital urethra, <b>MA Palinrungi.</b></li> </ul>	2011
<p>Trigonum Plus, Indonesian Surgeon Association, Makassar, Indonesia</p> <ul style="list-style-type: none"> <li>• Comparison of body mass index, aging male symptomsscore between rural and urban Indonesian males. <b>MA Palinrungi, D Rahardjo.</b></li> </ul>	2007
<p>The 4<sup>th</sup> Congress of the Asia Pacific Society for the Study of Aging Male (APSSAM) Conjunction education with the 28<sup>th</sup> Continuing Urological Education of the Indonesian Urological Association (CUE IUA), and 2<sup>nd</sup> Continuing education on sexual medicine of the Indonesian Association of Sexology (CESMIAS). Bali, Indonesia</p> <ul style="list-style-type: none"> <li>• Effect of age and comorbidity on perioperative complication and mortality of transvesical prostatectomy.</li> </ul>	2006

<p><b>MA Palinrungi</b>, R Danarto. The 8<sup>th</sup> Asian Congress of Urology. Bali, Indonesia</p> <ul style="list-style-type: none"> <li>• Penile fracture: evaluation of three cases. <b>MA Palinrungi</b>, AM Palinrungi. Congress of Indonesian Surgery Association. Jakarta, Indonesia</li> </ul>	2005
---	------

## PUBLIKASI JURNAL

	Period
<p>1. Encysted hydrocele of spermatic cord: a rare case report with review of literature AM Chairul, <b>MA Palinrungi</b>, M Faruk International Journal of Surgery Case Report</p>	2023
<p>2. A Giant Intra-abdominal testicular seminoma in a bilateral undescended testis: a case report M Faruk, <b>MA Palinrungi</b>, K Kholis, S Syahril, S Syarif, A Azis Pan African Medical Journal</p>	2023
<p>3. Traumatic Kidney Injury: A 6 -Year Retrospective Study in Childhood and Adolescence <b>MA Palinrungi</b>, R Cristeven, M. Faruk Preprint</p>	2022
<p>4. Ureteral avulsion is caused by through and-through penetrating injury of the pelvis. S Syahrir, K Kholis, <b>MA Palinrungi</b>, A Azis, S Syarif, A Zulfatulsyah, M Faruk International Journal of Surgery Case Report</p>	2022
<p>5. Malignant renal hemangiopericytoma: a case report. S Winoto, <b>MA Palinrungi</b>, K Kholis, S Syahrir, S Syarif, A Azis, M Faruk Pan African Medical Journal</p>	2022
<p>6. Primary Renal Non-Hodgkin Lymphoma: A Rare Case Report. RS Sujana, <b>MA Palinrungi</b>, G Arsyadi, UA Miskad, E Kodrat, M Faruk Surgery, Gastroenterology, and Oncology</p>	2022
<p>7. Priapism due to chronic myelocytic leukemia Syarif, K Kholis, <b>MA Palinrungi</b>, S Syahrir, A Azis, M Arfan Urology Case Report</p>	2022
<p>8. Penile Ischemia as a Complication of Epinephrine Use in Penile Nerve Block: Truth or Myth? <b>MA Palinrungi</b>, ALR Palinrungi, R Cristeven, M Faruk Research and Report in Urology</p>	2021
<p>9. The Effectiveness Between Tamsulosin and Solifenacin Combined with Tamsulosin on Treatment of Ureteral Stent-Related Symptoms. BE Hasbi, <b>MA Palinrungi</b>, K Kholis, S Bakri, S Syahrir, F Kasim.</p>	2021

- Nusantara Medical Science Journal
10. Neglected double-J stent with giant bladder stone: a case report  
K Kholis, **MA Palinruni**, S Syahrir, S Syarif, A Azis, S Ricardo, M Faruk  
Pan African Medical Journal  
2021
  11. Cut-off Point Prostate-Specific Antigen and Prostate-Specific Antigen Density in Prostate Cancer - Suspected Patients in Makassar, Indonesia.  
MI Gunadi, **MA Palinruni**, K Kholis, S Syahrir, Syarif, A Seweng, M Faruk  
Surgery, Gastroenterology, and Oncology  
2021
  12. Case Report: A rare case of renal-type clear cell carcinoma of the prostate  
**MA Palinruni**, R Masadah, K Kholis, S Syahrir, S Syarif, ALR Palinruni, E Krahmadi, M faruk.  
F1000Research 10 (475), 475  
Jun 2021
  13. Comparative effectiveness of Tamsulosin and Tadalafil therapy in ureteral stents-related symptoms (uSRS),  
MRF Ilyas, K Kholis, **MA Palinruni**, AM Palinruni, A Seweng, S Syahrir  
Medicina Clínica Práctica 4, 100226  
Apr 2021
  14. Primary anastomosis for complete bulbar urethral rupture with rectal laceration caused by straddle injury: a case report  
Syarif, **MA Palinruni**, K Kholis, S Syahrir, AP Pakan, M Faruk  
International Journal of Surgery Case Reports, 105848  
Apr 2021
  15. Penetrating scrotal injury in childhood  
**MA Palinruni**, K Kholis, Syarif, S Syahrir, HSP Nasution, M Faruk  
Urology Case Reports, 101635  
Mar 2021
  16. The effect of standing and sitting voiding position on uroflowmetric findings and postvoiding residual volume in men with Benign Prostatic Hyperplasia (BPH).  
RK Wijaya, K Kholis, S Syarif, **MA Palinruni**, S Syahrir, AA Zainuddin.  
Indonesia Journal of Biomedical Science 15(1):1-5  
DOI: 10.15562/ijbs.v15i1.247  
Dec 2020
  17. The association of prostatic inflammation grade with prostate volume and Prostate-Specific Antigen (PSA) value in Benign Prostate Hyperplasia (BPH) patients at Wahidin Sudirohusodo Hospital, Makassar.  
A Saleh, S Syahrir, **MA Palinruni**, K Kholis, S Syarif, A Seweng.  
Indonesia Journal of Biomedical Science 15(1):6-9  
DOI: 10.15562/ijbs.v15i1.246  
Dec 2020
  18. Renal trauma: a 5-year retrospective review in a single institution.  
S Syarif, AM Palinruni, K Kholis, **MA Palinruni**, S Syahrir, R Sunggiardi, M Faruk.  
Nov 2020

- Afr J Urol 26, 61 (2020).  
<https://doi.org/10.1186/s12301-020-00073-2>
19. Partial Penile Amputation due to Klingsor's Syndrome: A Case Report with a Successful Macroscopic Reconstruction.  
 S Syahrir, **MA Palinrungi**, K Kholis, S Syarif, M Faruk, R Christeven  
 International Journal of Surgery Case Report, 77(2020) 387-391.  
<https://doi.org/10.1016/j.ijscr.2020.10.141> Nov 2020
  20. Penile fracture in a Peyronie's disease patient: a case report  
 Nur Hidayatullah, K Kholis, **MA Palinrungi**, S Syahrir, S Syarif & M Faruk.  
*Afr J Urol* **26**, 43 (2020). [doi.org/10.1186/s12301-020-00054-5](https://doi.org/10.1186/s12301-020-00054-5) Oct 2020
  21. Bladder stones associated with vesicovaginal fistula: A case report.  
 Fransisca, K Kholis, **MA Palinrungi**, S Syahrir, Syarif, M Faruk.  
 International Journal of Surgery Case Report, 75 (2020) 122-125.  
 DOI: 10.1016/j.ijscr.2020.09.028 Sept 2020
  22. Multiple preputial stones: a care report and literature review.  
**MA Palinrungi**, K Kholis, S Syahrir, Syarif, M Faruk.  
 International Journal of Surgery Case Report, 70 (2020) 87-92.  
 DOI: 10.1016/j.ijscr.2020.04.041 May 2020
  23. Risk factors for urethrocutaneous fistula following hypospadias repair surgery in Indonesia.  
 GWK Duarsa, PMW Tirtayasa, B Daryanto, P Nurhadi, J Renaldo, Tarmono, T Utomo, P Yuri, S Siregar, I Wahyudi, GR Situmorang, **MA Palinrungi**, YI Hutasoit, AYA Hutahaeon, Y Zulfiqar, YH Sigumonrong, H Mirza, A Rodjani, YP Kloping. *Journal of Pediatric Urology*, Volume 16, Issue 3, June 2020, Pages 317.e1-317.e6  
<https://doi.org/10.1016/j.jpuro.2020.04.011> April 2020
  24. Fournier's gangrene in a two-month-old infant.  
**MA Palinrungi**, Sulmiati, SR Laiding, F Nurmantu, EP Madyaningtias, R Cristeven, M Faruk.  
*Journal of Pediatric Case Report*. 57:101447  
 DOI: 10.1016/j.epsc.2020.101447 April 2020
  25. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS).  
 E Palinggi, **MA Palinrungi**, AM Palinrungi, A Seweng, K Kholis, S Syahrir, Syarif, M Faruk.  
*J Med Allied Sci* 2020; 10(2):115-120  
 DOI: 10.5455/jmas.113358 Jan 2020
  26. Differences in Pain in Postoperative Cholecystectomy Laparotomy Patients with the Kocher Incision and Midline Incision Techniques.  
 JF Octarian, Warsingih, **MA Palinrungi**.  
*International Journal of Medical Reviews and Case Reports*  
 DOI: 10.5455/IJMRCR.2020-05-171-pain Jan 2020

- |   |           |
|---|-----------|
| <p>27. Effectiveness of Tamsulosin compared with Mirabegron in treatment of Double-J Stent-Related Lower Urinary Tract Symptoms.<br/>K Alexander, AM Palinruni, <b>MA Palinruni</b>, K Kholis, S Syahrir, Syarif, M Faruk.<br/>International Journal of Medical Reviews and Case Reports.<br/>DOI: 10.5455/IJMRCR.Double-J-Stent-Related-Lower-Urinary-Tract-Symptoms</p> | Jan 2020  |
| <p>28. Management of high grade blunt renal trauma in the pediatric patient, a five years retrospective study from a single institution in Indonesia.<br/><b>MA Palinruni</b>.<br/>Journal of Pediatric Urology, Volume 16, Supplement1, S36, January 01, 2020. (Proceeding)</p>  | Jan 2020  |
| <p>29. Giant bladder stone formed around sewing-needle in childhood: A case report and literature review.<br/><b>MA Palinruni</b>, K Kholis, S Syahrir, Syarif, M Faruk.<br/>Urology Case Report 29.<br/>DOI: 10.1016/j.eucr.2019.101101</p>  | Dec 2019  |
| <p>30. Profile of Urinary Stone in Makassar, Indonesia.<br/>Tommy Sulaksono, S Syahrir, <b>MA Palinruni</b>.<br/>International Journal of Research in Medical Sciences 7(12):4758<br/>DOI: 10.18203/2320-6012.ijrms20195552</p>   | Nov 2019  |
| <p>31. Incidentally found intra-renal teratoma in an adult: A case report and review of the literature.<br/><b>MA Palinruni</b>, P Prihantono.<br/>International Journal of Surgery and Medicine (2019) 5(4):230-233<br/>DOI: 10.5455/ijsm.teratoma-intrarenal</p>  | Sept 2019 |
| <p>32. Synchronous Invasive Urothelial Cell Carcinoma of the Bladder with Chronic Myeloid Leukemia - a Case Report<br/>S Syahrir, <b>MA Palinruni</b>, P Prihantono, M Faruk.<br/>International Journal of Surgery and Medicine (2019) 5(4):226-229<br/>DOI: 10.5455/ijsm.Synchronous-invasive-urothelial-cell-carcinoma</p>  | Oct 2019  |
| <p>33. Pediatric blunt renal trauma: a retrospective review from single institution, 5-year of experience (Supplement/proceeding)</p>   | Aug 2019  |
| <p>34. Renal trauma: 5 years evaluation in Makassar, Indonesia (Supplement/proceeding))</p>   | Aug 2019  |
| <p>35. A study of undescended testis in Makassar, Indonesia (Supplement/proceeding)</p>   | Aug 2019  |
| <p>36. Common Practice of Hypospadias Management by Pediatric Urologists in Indonesia: A Multi-center Descriptive Study from Referral Hospitals.<br/>GWK Duarsa, PMW Tirtayasa, B Daryanto, P Nurhadi, J Renaldo, Tarmono, T Utomo, P Yuri, S Siregar, I Wahyudi, GR Situmorang,</p>  | July 2019 |



- MA Palinrungi**, YI Hutasoit, AYA Hutahaeon, Y Zulfiqar, YH Sigumonrong, H Mirza, A Rodjani.  
Open Access Macedonian Journal of Medical Sciences 7(14)  
DOI: 10.3889/oamjms.2019.628
37. First case report of an adrenocortical carcinoma with ileal metastasis. April 2019  
MS Ramadhan, **MA Palinrungi**, WN Aisyah. In  
BJU International 2019 Apr 1 (Vol. 123, pp. 18-18). 111 River ST, Hoboken 07030-5774, NJ USA: Wiley. (Supplement/proceeding)
38. Giant Paravertebral Ganglioneuroma Saat inied with Scoliosis in Adolescent—a Case Report. April 2019  
P Imanullah, **MA Palinrungi**. Giant Paravertebral Ganglioneuroma Saat inied with Scoliosis in Adolescent—a Case Report. In  
BJU International 2019 Apr 1 (Vol. 123, pp. 10-10). 111 River ST, Hoboken 07030-5774, NJ USA: WILEY. (supplement/proceeding)
39. Simultaneous Penopubic Inverted VY Plasty and Creating New Penoscrotal Junction for Penile Lengthening after Partial Penectomy for Penile Carcinoma. Oct 2018  
**MA Palinrungi**. In  
Internantional Journal of Urology, 2018 Oct 1 (Vol. 25, pp. 429-429). 111 River ST, Hoboke 07030-5774, NJ USA: Wiley. (supplement/proceeding)
40. Metanephric Adenoma of the Kidney: A Case Report and Literature Review. Sept 2017  
**MA Palinrungi**, Prihantono Prihantono  
American Journal of Medical Case Reports. 2017, 5(9), 244-247.  
DOI: 10.12691/ajmcr-5-9-5
41. Characteristics and Treatment of Penile Paraffinoma in Makassar, Indonesia Oct 2017  
**MA Palinrungi**, Syakri Syahrir, Andhiny LR Palinrungi, Eko Krahmadi , Prihantono Prihantono  
American Journal of Medical Sciences and Medicine. 2017, 5(3), 53-55.  
DOI: 10.12691/ajmsm-5-3-3
42. Penile paraffinoma: Why they do it, how we treat it Aug 2017  
**MA Palinrungi**, S Syahrir  
International Journal of urology, 2017 (Supplement/proceeding)
43. Mesonephric carcinoma of the urinary bladder: case report and literature review Aug 2017  
**MA Palinrungi**, K Kholis, S Syahrir, G Arsyadi  
International Journal of urology, 2017 (Supplement/proceeding)
44. Tuberculosis of the prostate: case report and literature review Aug 2017  
**MA Palinrungi**, K Kholis, S Syahrir, G Arsyadi  
International Journal of urology, 2017 (Supplement/proceeding)
45. Correlation between testosterone and andropause Jul 2016  
James D Laly, **MA Palinrungi**, Achmad M Palinrungi

- |   |  |
|---|--|
| <p>BJU International, 2016 (Supplement/proceeding)</p> <p>46. Renal cell carcinoma: Seven years experience in Makassar, Indonesia<br/><b>MA Palinrungi</b><br/>International Journal of Urology 23:51-51 (Proceeding)</p> <p>47. Solitary neurofibroma adrenal gland, 1st report from Indonesia (case report and review of literature)<br/><b>MA Palinrungi</b><br/>International Journal of Urology 23:34-34 (Supplement/proceeding)</p> <p>48. POS01.84: The differences of AMS score and testosterone level between rural and urban areas<br/>Urology 70(3):215-215 (Supplement/proceeding)</p> <p>49. Comparison of body mass index, aging male symptomsscore between rural and urban male Indonesia<br/><b>MA Palinrungi</b>, Djoko Rahardjo, Akmal Taher<br/>The Aging Male 10(2)<br/>DOI: 10.1080/13685530701406911 (Supplement/proceeding)</p> <p>50. Effect of age and comorbidity on perioperative complication and mortality of transvesical prostatectomy<br/><b>MA Palinrungi</b>, Danarto HR<br/>International Journal of Urology 13(S1): A34<br/>DOI: 10.1111/j.1442-2042.2006.01621.x (Supplement/proceeding)</p> | <p>Jul 2016</p> <p>Jul 2016</p> <p>Sept 2007</p> <p>Jun 2007</p> <p>Aug 2006</p> |
|---|--|

## BUKU

- |   |                                   |
|---|-----------------------------------|
| <p>1. Guidelines for Paediatric Urology in Indonesia<br/>Chapter: Varicocele in children and adolescents<br/>GWK Duarsa, <b>MA Palinrungi</b></p> <p>2. Guidelines for Non-neurogenic lower urinary tract symptoms in women<br/>Chapter: Urethral Diverticula<br/>AD Santosa, <b>MA Palinrungi</b>, K Kholis, EY Rahman</p> | <p>Tahun<br/>2022</p> <p>2022</p> |
|---|-----------------------------------|

## PENDIDIKAN INFORMAL

- |   |  |
|---|--|
| <ul style="list-style-type: none"> <li>• The 22<sup>nd</sup> Annual Congress of Asia-Pacific Association of Paediatric Urology, Seoul, South Korea</li> <li>• The 12<sup>th</sup> Uro-Oncology Update, Urology Department, Faculty of Medicine, Universitas Indonesia</li> <li>• The 52<sup>nd</sup> Annual Meeting of the International Continence Society, Vienna, Austria</li> <li>• Webinar Circumcision, Indonesian Society of Paediatric Urology (InaSPU), Indonesian Urological Association</li> </ul> | <p>Period<br/>2022</p> <p>2022</p> <p>2022</p> <p>2022</p> |
|---|--|

• Prostate cancer masterclass webinar series. The Indonesian Urological Association	2022
• Basic Research Ethics and GCP (Good Clinical Practice) Training, Hasanuddin University	2022
• Guy & HKSE Virtual Grand Round: Kidney Series, Hongkong Society of Endourology	2021
• Webinar: The EAU/ESU Penile Cancer Reconstruction, European Accreditation Council of Continuing Medical Education	2021
• Workshop of National OSCE Examiners, Indonesian College of Surgery	2021
• Webinar: Satgas Covid-19 PP IAUI, Indonesian Urological Association	2021
• International Conference of Hypospadias (ISPU & ASPU Biennial Joint Meeting XXIII), Departement of Pediatric Surgery, All India Institute Medical Sciences	2021
• Jakarta Urology Medical Update (JUMP) in conjunction with Annual Scientific Meeting of Continence Society of Indonesia (PERKINA) 2021. Urology Department, Faculty of Medicine, Universitas Indonesia	2021
• The 12 <sup>th</sup> Uro-Oncology Update, Urology Department, Faculty of Medicine, Universitas Indonesia	2021
• Urofair Virtual 2021, Singapore Urological Association	2021
• The 43 <sup>rd</sup> Virtual-Annual Scientific Meeting Of the Indonesian Urological Association	Dec 2020
• Endourology Society: 12-Hour single Port SURS – WRSE Robotic Marathon. The University of California, Irvine School of Medicine	Dec 2020
• European Society of Pediatric Urology (ESPU) Virtual Meeting, Leuven (online), Belgium	Nov 2020
• The 40 <sup>th</sup> Urology symposium: CUHK Urology week. The Chinese University of Hong Kong & CUHK Jockey Club Minimally Invasive Surgical Skill Centre	Nov 2020
• i-True: International Training and Research in Uro-Oncology and Endourology. Module 4: Renal Cell Carcinoma	Nov 2020
• The British Association of Urological Surgeons (BAUS) Annual Meeting 2020	Nov 2020
• The 18th Urological Asian Association Congress (Virtual), Seoul, South Korea	Oct 2020
• The 40th Congress of Societe Internationale d’Urologie (Virtual).	Oct 2020
• Jakarta Urology Medical Update (JUMP) in conjunction with Annual Scientific Meeting of Continence Society of Indonesia (PERKINA) 2020. Andro-urology section	Oct 4 <sup>th</sup> 2020
• Jakarta Urology Medical Update (JUMP) in conjunction with Annual Scientific Meeting of Continence Society of Indonesia (PERKINA) 2020. PIT-Perkina section	Sept 26 <sup>th</sup> 2020
• Jakarta Urology Medical Update (JUMP) in conjunction with Annual Scientific Meeting of Continence Society of Indonesia (PERKINA) 2020. Oncology-urology and Live surgery section	Sept 17-19 <sup>th</sup> 2020
• Jakarta Urology Medical Update (JUMP) in conjunction with Annual Scientific Meeting of Continence Society of Indonesia (PERKINA) 2020. Endo-urology section	Sept 12 <sup>th</sup> 2020

<ul style="list-style-type: none"> <li>• Jakarta Urology Medical Update (JUMP) in conjunction with Annual Scientific Meeting of Continence Society of Indonesia (PERKINA) 2020. Andro-urology section</li> </ul>	Sept 6 <sup>th</sup> 2020
<ul style="list-style-type: none"> <li>• i-True: International Training and Research in Uro-Oncology and Endourology. Module 3: Urolithiasis</li> </ul>	Sept 2020
<ul style="list-style-type: none"> <li>• i-True: International Training and Research in Uro-Oncology and Endourology. Module 2: Prostate Cancer Localized</li> </ul>	Sept 2020
<ul style="list-style-type: none"> <li>• i-True: International Training and Research in Uro-Oncology and Endourology. Module 1: Prostate Cancer Localized</li> </ul>	Aug 2020
<ul style="list-style-type: none"> <li>• Prostate Cancer Focus Webinar. IAUI West Java Region/Dept Urology Hasan Sadiikin Hospital</li> </ul>	Aug 2020
<ul style="list-style-type: none"> <li>• i-True: International Training and Research in Uro-Oncology and Endourology. Stents: The lifeline of Endourology</li> </ul>	Aug 2020
<ul style="list-style-type: none"> <li>• The 13<sup>th</sup> Malang Continuing Urology Education (MCUE); “Urologist Collaboration Toward Better Urological Service in Indonesia”</li> </ul>	Jun 2020
<ul style="list-style-type: none"> <li>• Web series: BPH, Andro-urology, and Reconstruction</li> </ul>	
<ul style="list-style-type: none"> <li>• The 11<sup>th</sup> Uro-Oncology Update, Jakarta, Indonesia</li> </ul>	Feb 2020
<ul style="list-style-type: none"> <li>• The 21<sup>st</sup> Annual Asia Pacific Association of Paediatric Urology (APAPU), Perth, Australia</li> </ul>	Nov 2019
<ul style="list-style-type: none"> <li>• The 42<sup>nd</sup> Annual scientific meeting of the Indonesian urological association (ASMIUA), Banjarmasin, Indonesia</li> </ul>	Oct 2019
<ul style="list-style-type: none"> <li>• The 17<sup>th</sup> Urological Asian Association Congress, Kuala Lumpur, Malaysia</li> </ul>	Aug 2019
<ul style="list-style-type: none"> <li>• Continuing Urological Education, Department of Urology Cipto Mangunkusumo Hospital: “All about penis”, Jakarta. Indonesia</li> </ul>	Juni 2019
<ul style="list-style-type: none"> <li>• Urofair 2019, Singapore Urological Association, Singapore</li> </ul>	Apr 2019
<ul style="list-style-type: none"> <li>• The 10<sup>th</sup> Uro-Oncology Update, Solo, Indonesia</li> </ul>	Feb 2019
<ul style="list-style-type: none"> <li>• The 41<sup>st</sup> Annual scientific meeting of the Indonesian urological association (ASMIUA), Padang, Indonesia</li> </ul>	Oct 2018
<ul style="list-style-type: none"> <li>• Continuing Urological Education, Department of Urology Cipto Mangunkusumo Hospital: “All about incontinence”, Jakarta. Indonesia</li> </ul>	Aug 2018
<ul style="list-style-type: none"> <li>• The 16<sup>th</sup> Urological Asian Association Congress, Kyoto, Japan</li> </ul>	Apr 2018
<ul style="list-style-type: none"> <li>• The XXI Indonesian Surgery Association Congress, Makassar, Indonesia</li> </ul>	July 2018
<ul style="list-style-type: none"> <li>• The XX Continuing Medical Education, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia</li> </ul>	Jan 2018
<ul style="list-style-type: none"> <li>• The PCS 3<sup>rd</sup> World Congress of Urology, Athena, Greece</li> </ul>	Nov 2017
<ul style="list-style-type: none"> <li>• The 2<sup>nd</sup> Continuing Medical Education, Division of Urology, Department of Surgery, Faculty of Medicine, Hasanuddin University, The 1<sup>st</sup> Indonesian Urological Association Branch Makassar Symposia, <i>All About Prostate</i>, Makassar, Indonesia</li> </ul>	2017
<ul style="list-style-type: none"> <li>• The 2<sup>nd</sup> Continuing Medical Education, Division of Urology, Department of Surgery, Faculty of Medicine, Hasanuddin University, The 1<sup>st</sup> Indonesian Urological Association Branch Makassar Workshop, <i>All About Prostate</i>, Makassar, Indonesia</li> </ul>	2017
<ul style="list-style-type: none"> <li>• Second Continuing Medical Education, Faculty of Medicine, Moeslem University of Indonesia, Makassar, Indonesia</li> </ul>	2017
<ul style="list-style-type: none"> <li>• The 40<sup>th</sup> Annual scientific meeting of the Indonesian urological association (ASMIUA), Jogjakarta, Indonesia</li> </ul>	2017

- The 19<sup>th</sup> Annual Asia Pacific Association of Paediatric Urology (APAPU), Jogjakarta, Indonesia 2017
- The 15<sup>th</sup> Urological Asian Association Congress, Hongkong 2017
- The 1<sup>st</sup> Inagurs international workshop and symposium of reconstructional & functional Urology, Malang, Indonesia 2017
- The 10<sup>th</sup> Malang Continuing Urology Education 2017
- The 39<sup>th</sup> Annual scientific meeting of the Indonesian urological association (ASMIUA), Surabaya, Indonesia 2016
- Urology case in clinical case symposium, The 1<sup>st</sup> Continuing Medical Education, Division of Urology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia 2016
- The PCS 2<sup>nd</sup> World Congress of Urology, Marrakesh, Morocco 2016
- The 14<sup>th</sup> Urological Asian Association Congress, Singapore 2016
- Trainer Development Workshop, by Royal College of Surgery of Edinburg. Bandar Lampung, Indonesia 2016
- Live Surgery Courses, Genito-Urinary Reconstruction, Kulkarni School of Urethral Surgery, Pune, Indonesia 2016
- The 7<sup>th</sup> Uro-Oncology Update, Jakarta, Indonesia 2016
- Instructional Course on Radical Cystectomy, Jakarta, Indonesia 2016
- The 38<sup>th</sup> Annual scientific meeting of the Indonesian urological association (ASMIUA), Bali, Indonesia 2015
- The 13<sup>th</sup> Urological Asian Association Congress, Shanghai, China 2015
- The 6<sup>th</sup> Uro-Oncology Update, Jakarta, Indonesia 2015
- The 36<sup>th</sup> Continuing Medical Education, Faculty of Medicine, Hasanuddin University. *The basic science of Surgery (Congenital Anomaly)*, Makassar, Indonesia 2014
- The 37<sup>th</sup> Annual scientific meeting of the Indonesian urological association (ASMIUA): Stone and andrology, Lombok, Indonesia 2014
- Continuing Urological Education, Department of Urology Cipto Mangunkusumo Hospital: “All about penis: from newborn to elderly”, Jakarta. Indonesia 2014
- The 5<sup>th</sup> Uro-Oncology Update, Jakarta, Indonesia 2014
- The 15<sup>th</sup> Annual Congress of Asia Pacific Association of Pediatric Urology (APAPU): “When and How to Operate children”, TaipeiTzuchi Hospital, Taiwan 2013
- The Urology fiesta, Makassar, Indonesia 2013
- The 4<sup>th</sup> Uro-Oncology Update, Jakarta, Indonesia 2013
- The 35<sup>th</sup> Annual scientific meeting of the Indonesian urological association (ASMIUA), Jakarta, Indonesia 2012
- The 3<sup>rd</sup> Uro-Oncology update, Bali, Indonesia 2012
- The 3<sup>rd</sup> Scientific Meeting and Congress PERKINA: A multidisciplinary approach toward urinary continence”, Jakarta, Indonesia 2011
- The 2<sup>nd</sup> Uro-oncology update: Multidisciplinary approach in Uro-oncology towards better care for patients, Jakarta, Indonesia 2011
- Continuing Urological Education, Department of Urology Cipto Mangunkusumo Hospital: “All about Prostate”, Jakarta. Indonesia 2010

- Jakarta Urology Oncology Update. Jakarta, Indonesia 2010
- The 1st Asia Men's and Women's Health Summit, Hanoi, Vietnam 2010
- Update therapy for BPH, Urinary stone and female urology Symposia. Department of Urology/Cipto Mangunkusumo Hospital. Jakarta, Indonesia 2010
- The 17<sup>th</sup> Annual Scientific Meeting of Indonesian Surgeons Association, Manado, Indonesia 2010
- The 16<sup>th</sup> Annual Scientific Meeting of Indonesian Surgeons Association, Surabaya, Indonesia 2009
- The 32<sup>nd</sup> Annual Scientific Meeting of the Indonesian Urological association conjunction with the Urology Education Programme European School of Urology and Asian School of Urology. Bali, Indonesia 2009
- The 4<sup>th</sup> Congress of the Asia Pacific Society for the Study of Aging Male (APSSAM) Conjunction education with the 28<sup>th</sup> Continuing Urological Education of the Indonesian Urological Association (CUE IUA), and 2<sup>nd</sup> Continuing education on sexual medicine of the Indonesian Association of Sexology (CESMIAS). Bali, Indonesia 2007
- Continuing Medical Education-Profesional Development Unit (CME-PDU), Faculty of Medicine, University of Indonesia: Medical Journal Writing. Jakarta, Indonesia 2007
- Continuing Medical Education-Profesional Development Unit (CME-PDU), Faculty of Medicine, University of Indonesia: Urinary Incontinence. Jakarta, Indonesia 2007
- The 8<sup>th</sup> Asian congress of urology. Bali, Indonesia 2006
- A course of Paediatric and Reconstruction Surgery. Bali, Indonesia 2006
- Congress of Indonesian Surgery Association. Jakarta, Indonesia 2005
- The 1st National Scientific Meeting on Surgical Critical Care, Bandung, West Java, Indonesia 2004
- Course of Advance Trauma Live Support, Soppeng, South Sulawesi, Indonesia 2002
- The 4th National Congress of Indonesian Society of Oncology, Makassar, Indonesia 2002